Bridged aromatic substituted amine ligands with donor atoms

ABSTRACT

The present invention provides for substituted metal chelating compounds in which at least two of the chelating atoms are nitrogen which are directly attached to aromatic rings and one or more of those nitrogen atoms has attached thereto a substituent other than hydrogen, and methods for making and using these compounds.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No.09/724,834, filed Nov. 28, 2000, now U.S. Pat. No. 6,528,627; whichapplication is a continuation of U.S. patent application Ser. No.09/310,455, filed May 12, 1999, which issued as U.S Pat. No. 6,187,910;which application is a divisional of U.S. patent application Ser. No.08/829,533, filed Mar. 28, 1997, which issued as U.S. Pat. No.6,005,083; all of which applications are incorporated by referenceherewith in their entirety.

TECHNICAL FIELD

The present invention relates generally to chelation compounds,radionuclide metal chelate compounds (i.e., complexes) and radiolabeledtargeting moieties (i.e., conjugates) formed therefrom, and methods ofmaking and using these compounds, complexes and conjugates fordiagnostic and therapeutic purposes. This invention is more particularlyrelated to compounds in which at least two of the chelating atoms arenitrogen atoms which are directly attached to aromatic rings and thereis a non-hydrogen substituent directly attached to at least one of thesenitrogen chelating atoms.

BACKGROUND OF THE INVENTION

Radiolabeled chelation compounds have been studied and used aspharmaceuticals for diagnostic and therapeutic purposes for a number ofyears. The requirements for a useful radiolabeled chelating compound arewell known to those skilled in the art of nuclear medicine andradiopharmaceutical research. Briefly, these requirements include:efficient final preparation of the radiopharmaceutical, such thatpreparation in the hospital or pharmacy is possible; efficient transportof the radiopharmaceutical to the target organ; efficient extraction ofthe radiopharmaceutical by the target organ, such that adequate targetto background ratios are achieved to allow diagnostic and therapeuticdistinctions; and adequate retention in the target organ to allowdetection and therapy using conventionally available radiationmonitoring equipment. Representative organs of interest are thosecontaining malignant cells or activated platelets. Imaging agents andtherapeutic agents have typically been unsuitable due to poor in vivostability post-chelation, resulting in inadequate retention andaccretion by the effected cells.

Thus, there is a need in the art for improved chelation compounds forimaging and therapy. The present invention fulfills this need andfurther provides other related advantages.

SUMMARY OF THE INVENTION

Briefly stated, the present invention in one aspect provides compoundshaving the formula:

wherein:

-   -   n=0 or 1;    -   R₁ and R₂ are independently selected from hydrogen, ═O, with the        proviso that both are not ═O, —(CH₂)_(m)-Z where m is 0-10 and Z        represents a conjugation group or targeting moiety, and        —(Ch₂)_(m)—W where m is 0-10 and W represents a hydrolyzable        group, or R₁ and R₂ are taken together to form a cyclic        anhydride or a benzene ring;    -   R₃ is hydrogen, lower alkyl, alkoxy, halogen, hydroxyl, nitro,        —(CH₂)_(m)-Z or —(CH₂)_(m)—W;    -   R₄ and R₅ are attached at one or more of the ring positions and        are independently selected from hydrogen, lower alkyl, alkoxy,        halogen, hydroxyl, nitro, —(CH₂)_(m)-Z and —(CH₂)_(m)—W;    -   R₆ and R₇ are independently selected from hydrogen with the        proviso that both are not hydrogen, lower alkyl, alkoxy,        halogen, hydroxyl, nitro, —(CH₂)_(m)-Z, —(CH₂)_(m)—W and        where Q represents a multivalent acid functionality group able        to coordinate with metal ions, and p=0 to 1; R₁₂ and R₁₃ are        independently selected from hydrogen, hydroxyl, carboxyl,        phosphonic and hydrocarbon radicals having from 1-10 carbon        atoms, and physiologically acceptable salts of the acid        radicals;    -   X, X′, Y and Y′ are independently selected from carbon,        nitrogen, oxygen and sulfur to independently form five or six        member aromatic rings wherein the remaining ring atoms are        carbon;    -   A and A′ are independently selected from sulfur, nitrogen and        oxygen, where sulfur may bear a hydrogen or a sulfur protecting        group, or where A and A′ are both sulfur, A and A′ may be joined        together by a bond; where an oxygen or a nitrogen may bear a        hydrogen; or where A or A′ is nitrogen, A may bear R₈ or R₁₀ or        both and A′ may bear R₉ or R₁₁ or both, wherein R₈, R₉, R₁₀ and        R₁₁ are independently selected from lower alkyl, alkoxy,        halogen, hydroxyl, nitro, —(CH₂)_(m)-Z, —(CH₂)_(m)—W and        or R₈ and R₁₀ may be joined to form a cyclic anhydride or R₉ and        R₁₁ may be joined to form a cyclic anhydride; or when A and A′        are both nitrogen, R₁₀ and R₁₁ may be joined to form T, where T        is        and n is 0 to 1, and R₁′ and R₂′ are independently selected from        hydrogen, ═O, with the proviso that both are not ═O,        —(CH₂)_(m)-Z and —(CH₂)_(m)—W or R₁′ and R₂′ are taken together        to form a cyclic anhydride or a benzene ring; and R₃′ is        hydrogen, lower alkyl, alkoxy, halogen, hydroxyl, nitro,        —(CH₂)_(m)-Z and —(CH₂)_(m)—W; and    -   said compound has at least one Z, W and Q.

In another aspect, the invention provides chelates comprisingradionuclide metals (including oxides or nitrides thereof) complexed bya compound described above A preferred metal chelate compound is of theformula:

wherein:

-   -   M is a radionuclide metal or an oxide or a nitride thereof        selected from technetium, copper, rhenium, sumarian, yttrium,        indium, lead, bismuth, ruthenium, rhodium, gold and palladium;    -   n=0 or 1;    -   R₁ and R₂ are independently selected from hydrogen, ═O with the        proviso that both are not ═O, —(CH₂)_(m)-Z where m is 0-10 and Z        represents a conjugation group or targeting moiety, and        —(CH₂)_(m)—W where m is 0-10 and W represents a hydrolyzable        group, or R₁ and R₂ are taken together to form a cyclic        anhydride or a benzene ring;    -   R₃ is hydrogen, lower alkyl, alkoxy, halogen, hydroxyl, nitro,        —(CH₂)_(m)-Z or —(CH₂)_(m)—W;    -   R₄ and R₅ are attached at one or more of the ring positions and        are independently selected from hydrogen, lower alkyl, alkoxy,        halogen, hydroxyl, nitro, —(CH₂)_(m)-Z and —(CH₂)_(m)—W;    -   R₆ and R₇ are independently selected from hydrogen with the        proviso that both are not hydrogen, lower alkyl, alkoxy,        halogen, hydroxyl, nitro, —(CH₂)_(m)-Z, —(CH ₂)_(m)—W— and        where Q represents a multivalent acid functionality group able        to coordinate with metal ions, and p=0 to 1; R₁₂ and R₁₃ are        independently selected from hydrogen, hydroxyl, carboxyl,        phosphonic and hydrocarbon radicals having from 1-10 carbon        atoms, and physiologically acceptable salts of the acid        radicals;    -   X, X′, Y and Y′ are independently selected from carbon,        nitrogen, oxygen and sulfur to independently form 5 or 6 member        aromatic rings wherein the remaining ring atoms are carbon;    -   A and A′ are independently selected from sulfur, nitrogen and        oxygen, where A or A′ is nitrogen, A may bear R₈ or R₁₀ or both        and A′ may bear R₉ or R₁₁ or both, wherein R₈, R₉, R₁₀ and R₁₁        are independently selected from lower alkyl, alkoxy, halogen,        hydroxyl, nitro, —(CH₂)_(m)-Z, —(CH₂)_(m)—W and        or R₈ and R₁₀ may be joined to form a cyclic anhydride or R₉ and        R₁₁ may be joined to form a cyclic anhydride; or when A and A′        are both nitrogen, R₁₀ and R₁₁ may be joined to form T, where T        is        and n is 0 to 1, and R₁′ and R₂′ are independently selected from        hydrogen, ═O, with the proviso that both are not ═O,        —(CH₂)_(m)-Z or R₁′ and R₂′ are taken together to form a cyclic        anhydride or a benzene ring; and R₃′ is hydrogen, lower alkyl,        alkoxy, halogen, hydroxyl, nitro, —(CH₂)_(m)-Z or —(CH₂)_(m)—W;        and    -   said compound has at least one Z, W or Q.

Yet another aspect of the invention provides for the use of thechelation compounds described above in methods for diagnostic andtherapeutic purposes. A diagnostic method is described for detecting thepresence or absence of a target site within a mammalian host This methodcomprises providing to cells a diagnostically effective dose of acompound of the present invention which contains a metal radionuclide,such as ^(99m)TC and/or ¹¹¹In, and detecting the biodistribution of theradionuclide. A therapeutic method is described for delivering aradionuclide, such as ¹⁸⁶Re/¹⁸⁸Re, ⁹⁰Y, and ¹⁵³Sm, to a target sitewithin a mammalian host. This method comprises providing to cells atherapeutically effective dose of a chelate compound of the presentinvention.

Other aspects of the invention will become evident upon reference to thefollowing detailed description.

DETAILED DESCRIPTION OF THE INVENTION

Prior to setting forth the invention, it may be helpful to anunderstanding thereof to set forth definitions of certain terms to beused hereinafter.

Targeting moiety—is any molecule that binds to a defined population ofcells, and includes analogs of naturally occurring and synthetically orrecombinantly prepared molecules. The targeting moiety may bind areceptor, an oligonucleotide, an enzymatic substrate, an antigenicdeterminant, or other binding site present on or in the target cellpopulation. For example, a protein may be a targeting moiety. Antibodiesand peptides are used throughout the specification as prototypicalexamples of targeting moieties. Tumor is used as a prototypical exampleof a target in describing the present invention.

Protein—as used herein, includes proteins, fusion proteins, polypeptidesand peptides; and may be an intact molecule, a fragment thereof, or afunctional equivalent thereof; and may be genetically engineered.

Antibody—as used herein, includes both polyclonal and monoclonalantibodies; and may be an intact molecule, a fragment thereof, or afunctional equivalent thereof; and may be genetically engineered;examples of antibody fragments include F(ab′)₂, Fab′, Fab and Fv.

The present invention provides chelation compounds and radionuclidemetal chelate compounds (i.e., complexes) prepared therefrom, as well asradiolabeled targeting moieties having the chelation compounds orchelates attached thereto (i.e., conjugates). The radionuclide metalchelates of the present invention may be attached to targeting moieties,such as antibodies and proteins, to form radiolabeled targeting moietieshaving diagnostic and therapeutic use Alternatively, the radionuclidemetal chelates of the present invention may be used for diagnostic andtherapeutic purposes without attachment to targeting moieties.

The present invention provides compounds that have a variety of uses,including for malignant cell imaging and therapy as well as thrombusimaging. The compounds are capable of rapidly complexing a metal as wellas forming a stable metal chelate (complex). The presence of nitrogenatoms within the chelating compound accelerates complex formation withthe metal. This acceleration is due in part to the fact that a metal(e.g., technetium) is a soft acid, and nitrogen (in the form of an amineor amide) is a base. Amines generally provide for a greater increase inchelation rates than amides Where sulfur atoms are additionally presentwithin the chelating compound, they also provide for an increased rateof metal complexation and contribute to the stability of the resultingchelate The presence of phenolic hydroxyl groups within the chelatingcompound aid in faster kinetics of metal ion chelation The compounds ofthe present invention are characterized by desirable metal complexformation kinetic properties and desirable metal-chelate retentionthermodynamic properties. The compounds of the present invention havethe further advantage of nitrogen atoms attached directly to aromaticrings which aid in fast kinetics of chelation and further enhances thestability of the aromatic esters of this invention with respect tohydrolysis in the bloodstream. Furthermore, an additional advantage ofthe present invention is the presence of substituents attached to thenitrogen atoms within the chelating compound, which imparts a higherbasicity to the chelation compound and allows for additional donor atomsfor complexation, thereby expanding the type of radionuclides useful forradiotherapy and radiodetection in the present invention. In addition tothe above advantages, the presence of substituents enhancespharmakokinetics and pharmacodynamics, such as the biopharmaceuticalproperties (i.e, absorption, distribution, metabolism and excretion).

The chelation compounds of the present invention have the followingformula (I):

Examples of specific embodiments of the elements of the above formulainclude the following.

-   -   R₁ and R₂ may be independently selected from hydrogen (H); an        oxy group (═O); —(CH₂)_(m)-Z where m is 0-10 and Z represents a        conjugation group or targeting moiety; or —(CH₂)_(m)—W where m        is 0-10 and W represents a hydrolyzable group. As used herein,        the phrase independently selected means the selection of one        substituent may be made without regard for the selection of any        other substituent. Alternatively, R₁ and R₂ may be taken        together to form a cyclic group, such as an anhydride or a        benzene ring. As used herein, a benzene ring may be benzene or        benzene with one or more substituents. A substituent may be any        electron donating (methyl, methoxy, amino and the like) and/or        electron withdrawing (halogens, nitro, carboxy, nitrile and the        like) and functional groups (esters, imidates, carbaminates and        the like) known in the art. Examples of such substituents        include Cl, CH₃, OCH₃, F, Br, I, CF₃ and a triazene, such a        —N═N—N (CH₃)₂.

As noted above, Z represents a conjugation group or a targeting moiety.A “conjugation group” in the compounds of the present invention is anychemically reactive group capable of forming a covalent bond with atargeting moiety under conditions that do not adversely affect thetargeting moiety's functional properties. For example, where thetargeting moiety is a protein such as an antibody, the conjugation groupis sufficiently reactive with a functional group on the protein so thatthe reaction can be conducted in substantially aqueous solutions anddoes not have to be forced (e.g., by heating to high temperatures whichmay denature the protein).

A conjugation group may be strongly electrophilic or nucleophilic andthereby capable of reacting directly with a targeting moiety. Aprecursor to a conjugation group may be a weaker electrophile ornucleophile that requires activation prior to conjugation with atargeting moiety. Conversion of a group from a precursor group to aconjugation group is generally performed in a separate step prior toconjugation with a targeting moiety. However, where a targeting moietyis unreactive with the conversion reagents and unaffected by thereaction conditions, it is possible to generate a conjugation group inthe presence of the targeting moiety.

An electrophilic conjugation group may react directly with anucleophile, either through nucleophilic substitution or nucleophilicaddition. In the present invention, electrophilic conjugation groupsreact with the targeting moiety acting as the nucleophile. A targetingmoiety may naturally possess nucleophilic group(s). For example, atargeting moiety may contain an amino group or a sulfhydryl group.Alternatively, a targeting moiety may have been modified to containnucleophilic group(s). Procedures for modifying molecules to containnucleophilic groups are well known to those in the art (see, e.g.,catalog of Pierce Chemical Co., Rockford, Ill., and U.S. Pat. No.4,659,839).

Electrophilic groups which provide conjugation through nucleophilicsubstitution include those groups which contain substituents which arereadily displaced. Such readily displaced substituents are commonlyreferred to as leaving groups. Leaving groups include halides which arereadily displaced from alkyl halides and alphahalo carbonyl compounds,and carboxylate and stabilized oxyanions which are readily displacedfrom carbonyl-containing groups such as anhydrides and active esters,respectively. For example, in addition to halide ion leaving groups suchas iodide, bromide, and chloride ions, other leaving groups includecarboxylate ions such as acetate and trifluoroacetate and phenolate ionssuch as phenolate and p-nitrophenolate as well as tosylates andmesylates. Suitable active ester groups include N-hydroxysuccinimidyl,tetrafluorophenyl, nitrophenyl, and 1-hydroxybenzotriazolyl.

Electrophilic groups which provide conjugation through nucleophilicaddition include those groups which contain unsaturated carbon atomssusceptible to nucleophilic addition. Suitable electrophilic carbonspecies include thiocyanates, isocyanates, isothiocyanates andmaleimides.

As mentioned above, a conjugation group capable of reacting directlywith a targeting moiety may be prepared by conversion of a weakerelectrophilic or nucleophilic group to a stronger one. For example, acarboxylic acid group is a precursor group which may be activated,(e.g., by conversion into an active ester conjugation group capable ofreaction with targeting moieties as described above). Another example ofa conversion to a strong electrophilic group is deprotection of aphenylsulfonyl succinimide to provide a maleimide capable of reactionwith nucleophilic targeting moieties as described above.

The conjugation group may also be a nucleophilic group, such as an aminoor sulfhydryl group. Such a nucleophile is capable of reacting with anelectrophilic targeting moiety, such as one that naturally possesseselectrophilic group(s) or one that has been modified to includeelectrophilic group(s). For example, a targeting moiety may contain anactive ester or a maleimide group. Alternatively, procedures formodifying molecules to contain electrophilic groups are well known tothose in the art (see, e.g., catalog of Pierce Chemical Co., Rockford,Ill., and U.S. Pat. No. 4,671,958).

Alternatively, Z may be a targeting moiety rather than a conjugationgroup. A “targeting moiety” in the compounds of the present inventionhas the functional property that it binds to a defined target cellpopulation, such as tumor cells. Preferred targeting moieties useful inthis regard include proteins, peptides, antibody and antibody fragments,hormones, and vitamins such as biotin. Proteins corresponding to knowncell surface receptors (including low density lipoproteins, transferrinand insulin), fibrinolytic enzymes, anti-HER2, platelet binding proteinssuch as annexins, avidin, streptavidin, and biological responsemodifiers (including interleukin, interferon, erythropoietin,colony-stimulating factor, TNF-tissue necrosis factors and similarcytokines) are also preferred targeting moieties. Also, anti-EGFreceptor antibodies, which internalize following binding to the receptorand traffic to the nucleus to an extent, are preferred targetingmoieties for use in the present invention to facilitate delivery ofAuger emitters and nucleus binding drugs to target cell nuclei.Oligonucleotides, e.g., antisense oligonucleotides that arecomplementary to portions of target cell nucleic acids (DNA or RNA), arealso useful as targeting moieties in the practice of the presentinvention. Oligonucleotides binding to cell surfaces are also useful.Analogs, including those of the above-listed targeting moieties, thatretain the capacity to bind to a defined target cell population may alsobe used within the claimed invention. In addition, synthetic orrecombinant targeting moieties may be designed and produced.

Functional equivalents of the aforementioned molecules are also usefulas targeting moieties of the present invention. An example of atargeting moiety functional equivalent is a “mimetic” compound, which isan organic chemical construct designed to mimic the proper configurationand/or orientation for targeting moiety-target cell binding. Anotherexample of a targeting moiety functional equivalent is a shortpolypeptide designated as a “minimal” polypeptide. Such a polypeptide isconstructed using computer-assisted molecular modeling and mutantshaving altered binding affinity of the targeting moiety.

As disclosed above, preferred targeting moieties of the presentinvention are proteins, antibodies (polyclonal or monoclonal), peptides,oligonucleotides or the like. Polyclonal antibodies useful in thepractice of the present invention are polyclonal (Vial and Callahan,Univ. Mich. Med. Bull. 20:284-6, 1956), affinity-purified polyclonal orfragments thereof (Chao et al., Res. Comm. in Chem. Path. & Pharm.(:749-61, 1974).

Monoclonal antibodies useful in the practice of the present inventioninclude whole antibody and fragments thereof. Such monoclonal antibodiesand fragments are producible in accordance with conventional techniques,such as hybridoma synthesis, recombinant DNA techniques and proteinsynthesis. Useful monoclonal antibodies and fragments may be derivedfrom any species (including humans) or may be formed as chimericproteins which employ sequences from more than one species See,generally, Kohler and Milstein, Nature 256:495-97, 1975; Eur. J.Immunol. 6:511-19, 1976.

Human monoclonal antibodies or “humanized” murine antibody are alsouseful as targeting moieties in accordance with the present invention.For example, a murine monoclonal antibody may be “humanized” bygenetically recombining the nucleotide sequence encoding the murine Fvregion (i.e., containing the antigen binding sites) or the complementarydetermining regions (“CDR's”) thereof with the nucleotide sequenceencoding a human constant domain region and an Fc region (i.e., humanframework), e.g., in a manner similar to that disclosed in U.S. Pat.Nos. 4,816,397, 4,816,567, 5,530,101 and 5,585,089. Some murine residuesmay also be retained within the human variable region framework domainsto ensure proper target site binding characteristics. Humanizedtargeting moieties are recognized to decrease the immunoreactivity ofthe antibody or polypeptide in the host recipient, permitting anincrease in the half-life and a reduction in the possibility of adverseimmune reactions.

Another preferred targeting moiety of the present invention is anannexin and other platelet binding proteins, such as PAP-1 (PlacentalAnticoagulant Protein or Annexin V). Annexins are (with the exception ofannexin II), single-chain, non-gylcosylated protein of approximately 36kilodaltons. In the presence of calcium, these proteins have anespecially high affinity for negatively-charged phospholipids, such asphosphatitylserine.

As mentioned above, W is a hydrolyzable group. As used herein, the term“hydrolyzable group” refers to any neutral organic group that provides acharged group upon hydrolysis. The hydrolysis may be chemical orenzymatic in nature. Examples of hydrolyzable groups include esters,imidates, and nitrites which may be hydrolyzed to carboxylic acids; andcarbamates which may be hydrolyzed to amines.

Referring to the above formula, the distance by which the chelatingnitrogen atoms are separated may be increased by interposing a methylenegroup, —CH₂—, between the carbon atoms bonded to the nitrogens depicted.When no methylene group is interposed, represented in the above formulawhere n=0, the chelating nitrogens are separated by two carbon atoms.When n=1, the interposed methylene group may be substituted with R₃.

R₃ may be hydrogen, a lower alkyl group, an alkyl group, an alkoxygroup, a halogen, a hydroxyl group, a nitro group, —(CH₂)_(m)-Z or—(CH₂)_(m)—W. As used throughout, a lower alkyl group is an alkyl groupof hydrocarbon radicals having from 1-10 carbon atoms, andphysiologically acceptable salts of the acid radicals which includes asubstituted lower alkyl. A substituted lower alkyl group is a loweralkyl group that bears a halogen, perhaloalkyl, hydroxyl or alkoxysubstituent; an alkoxy group is any alkoxy group of C₆ or less. Suitablehalogens include fluorine, chlorine, bromine and iodine.

R₄ and R₅ may be attached at one or more of the aromatic ring positions,preferably the ring carbon atoms. R₄ and R₅ are independently selectedfrom hydrogen, a lower alkyl group, an alkoxy group, a halogen, ahydroxyl group, a nitro group, —(CH₂)_(m)-Z and —(CH₂)_(m)—W. For R₄ andR₅, preferred groups include lower alkyl groups such as methyl, alkoxygroups such as methoxy, and halogen groups such as fluorine. Preferred Zgroups include active esters such as N-hydroxysuccinimide esters andmaleimides. Preferred W groups include ester and carbamate groups, suchas ethyl esters and ethyl carbamates. Preferably, such preferred alkylgroups, alkoxy groups, and ester groups are substituted at the aromaticring carbon ortho or para to the chelating nitrogen depicted in formulaI above.

R₆ and R₇ may be independently a hydrogen, lower alkyl, alkoxy, halogen,hydroxyl, nitro, —(CH₂)_(m)-Z, —(CH₂)_(m)—W and

where Q represents a multivalent acid functionality capable ofcoordinating with metal ions, and p=0 to 1; R₁₂ and R₁₃ areindependently selected from hydrogen, hydroxyl, carboxyl, phosphonic,and hydrocarbon radicals having from 1-10 carbon atoms, andphysiologically acceptable salts of the acid radicals, and R₁₂ and R₁₃may be the same as or different from one another. In one embodiment, R₇may be hydrogen when R₆ is

and Q is a phosphonic or a carboxylic acid and R₆ may be hydrogen whenR₇ is

and Q is a phosphonic or a carboxylic acid, but R₆ and R₇ cannot both behydrogen simultaneously. As noted above, Q represents a multivalent acidfunctionality. As used herein, the term multivalent acid functionalityrefers to any multivalent acid capable of coordinating a metal ion knownto one of ordinary skill in the art. In preferred embodiments, R₆ or R₇or both bear a Q containing substituent. Preferred multivalent acids arethe following: a phosphonic acid, a carboxylic acid, a thioacetic acidand a sulfonic acid. Particularly preferred are a phosphonic acid and acarboxylic acid. The multivalent acid provides extra donor atoms whichallow for binding of a metal through coordination of such donor atoms,thereby providing for a versatile chelation compound for diagnostic andtherapeutic use.

The compounds of the present invention typically have one or more Q, Zand/or W groups. For example, a compound may have one Z or one W or oneQ, or a combination of all three or some lesser combination.Alternatively, for example, a compound may have multiple Z and/ormultiple W groups, and/or multiple Q groups.

A and A′ may be independently selected from nitrogen, oxygen and sulfur.Where a sulfur is present, it may bear a hydrogen or a sulfur protectinggroup. Where A and A′ are both sulfur, they may be joined together by abond or any sulfur protecting group known in the art. Where an oxygen ora nitrogen is present, it may bear a hydrogen. Where A or A′ isnitrogen, A may bear R₈ or R₁₀ or both and A′ may bear R₉ or R₁₁ orboth, wherein R₈, R₉, R₁₀ and R₁₁ are independently selected from alower alkyl, alkoxy, halogen, hydroxyl, nitro, —(CH₂)_(m)-Z,—(CH₂)_(m)—W and

where Q represents a multivalent acid functionality capable ofcoordinating with metal ions, and p=0 to 1; R₁₂ and R₁₃ areindependently selected from hydrogen, hydroxyl, carboxyl, phosphonic,and hydrocarbon radicals having from 1-10 carbon atoms, andphysiologically acceptable salts of the acid radicals, and R₁₂ and R₁₃may be the same as or different from one another; R₈ and R₁₀ may bejoined to form a cyclic anhydride or R₉ and R₁₁ may be joined to form acyclic anhydride. Where A and A′ are both nitrogen, R₁₀ and R₁₁ may bejoined to form T, where T is

and n is 0 to 1. R₁′ and R₂′ may be independently selected fromhydrogen, ═O, —(CH₂)_(m)-Z and —(CH₂)_(m)—W, or R₁′ and R₂′ are takentogether to form a cyclic anhydride or a benzene ring. R₃′ is selectedfrom hydrogen, lower alkyl, substituted lower, alkoxy, perhaloalkoxy,perhaloalkyl, halogen, hydroxyl, nitro, —(CH₂)_(m)-Z and —(CH₂)_(m)—W Ina preferred embodiment where A and A′ are both sulfur, the sulfur atomsare joined together by a bond thus forming a disulfide. In a preferredembodiment where A and A′ are both nitrogen, R₁₀ and R₁₁ are joined toform T where n is either 0 or 1 and R₈ and R₉ are

where Q represents multivalent acid functionality capable ofcoordinating with metal ions, and m=0 to 1; R₁₂ and R₁₃ areindependently selected from hydrogen, hydroxyl, carboxyl, phosphonic,and hydrocarbon radicals having from 1-10 carbon atoms, andphysiologically acceptable salts of the acid radicals, and R₁₂ and R₁₃may be the same as or different from one another.

The chelation compounds of the present invention may be categorized bythe number and type of chelating atoms (i.e. N_(x)S_(y)O_(z) where x is2 to 4, y is 0 to 2, and z is 0 to 2). For example, where both A and A′are nitrogen, the chelation compounds of the present invention are ableto bind a metal through coordination with all four nitrogen atoms. Sucha chelating compound may be referred to as an “N₄” (N₄S₀O₀) compound. Inanother embodiment, both A and A′ are sulfur, resulting in the capacityfor metal chelation through two nitrogen atoms and two sulfur atoms, andthus providing an “N₂S₂” (N₂S₂O₀) chelating compound. Alternatively, Amay be nitrogen and A′ may be sulfur or A may be sulfur and A′ may benitrogen. Either of these embodiments are capable of metal chelationinvolving three nitrogen atoms and a single sulfur atom, an “N₃S”(N₃S₁O₀) chelating compound. In another embodiment, A and/or A′ may beoxygen atoms (e.g., hydroxyl groups). Where both A and A′ are oxygen, an“N₂O₂” (N₂S₀O₂) chelating compound results. Other embodiments include“N₃O” (N₃S₀O₁) and “N₂SO” (N₂S₁O₁) chelation compounds where one ofeither A or A′ is oxygen and the other is nitrogen or sulfur,respectively.

In a preferred embodiment of the present invention, the chelationcompounds are able to bind a metal radionuclide with the donor atomsproviding up to eight coordination sites For example, A and A′ are bothnitrogen, R₁₀ and R₁₁ may join the two nitrogen atoms, through theformation of T to create a cyclic “N₄” (N₄S₀O₀) chelation compound andwherein R₆, R₇, R₈ and R₉ may be

wherein Q is preferably a multivalent acid functionality, such as aphosphonic and/or a carboxylic acid. Thus, in addition to the fourchelating atoms of nitrogen, the oxygen atoms of the multivalent acidfunctionality provide up to four additional coordination sites, therebyexpanding the type of radionuclide that is useful in this invention(e.g., Indium and Yttrium)

As noted above, the sulfur atoms of the chelation compounds may bearsulfur protecting groups. Suitable sulfur protecting groups include anyof the alkyl, acyl, and aryl groups, disulfides and bunte salts known bythose of ordinary skill in the art. Preferred sulfur protecting groupsare those that result in the formation of thioacetal, hemithioacetal,thioketal, hemithioketal, thioester or acetamidomethyl substituent.Particularly preferred groups include p-anisylidine, acetonyl,tetrahydrylfuranyl, ethoxyethyl, tetrahydrylpyranyl, acetamidomethyl andderivatives thereof. When conjugating a chelating compound of thepresent invention to a targeting moiety, the protecting groups may beremoved just prior to metal complexation or during the radiolabelingreaction.

An acetamidomethyl sulfur-protecting group is represented by thefollowing formula, wherein the sulfur atom shown is a sulfur donor atomof the chelating compound:

The acetamidomethyl group is displaced from the chelating compoundduring radiolabeling conducted at about 50° C. in a reaction mixturehaving a pH of about 3 to 6.

When hemithioacetal protective groups are used, each sulfur atom to beprotected has a separate protective group attached to it, which togetherwith the sulfur atom defines a hemithioacetal group. The hemithioacetalgroups contain a carbon atom bonded directly (i.e., without anyintervening atoms) to a sulfur atom and an oxygen atom, i.e.,

Preferred hemithioacetals generally are of the following formula,wherein the sulfur atom is a sulfur atom of the chelating compound, anda separate protecting group is attached to each of the sulfur atoms onthe chelating compound:

wherein R^(a) is a lower alkyl group, preferably of from 2-5 carbonatoms, and R^(b) is a lower alkyl group, preferably of from 1-3 carbonatoms Alternatively, R^(a) and R^(b) may be taken together with thecarbon atom and the oxygen atom shown in the formula to define anonaromatic ring, preferably comprising from 3-7 carbon atoms inaddition to the carbon and oxygen atoms shown in the formula. R^(c)represents hydrogen or a lower alkyl group wherein the alkyl grouppreferably is of from 1-3 carbon atoms Examples of such preferredhemithioacetals include, but are not limited to:

In one embodiment of the present invention, the sulfur protecting groupsmay join the two sulfur chelating atoms. Preferred embodiments of thesulfur protecting groups include thioketals and thioacetals, which maybe prepared by condensation of the sulfur containing chelating compoundwith ketones and aldehydes, respectively. These particular sulfurprotecting groups are represented by the following formula, wherein thesulfur atoms shown are the sulfur donor atom of the chelating compound:

In the formula, R^(d) and R^(e) are independently selected fromhydrogen, lower alkyl groups (preferably methyl or ethyl), lower alkoxygroups (preferably containing one or two carbon atoms), aryl groups, ortaken together form a cyclic group (preferably a cyclopentane orcyclohexane ring).

These sulfur-protective groups are displaced during the radiolabelingreaction, conducted at acidic pH, in what is believed to bemetal-assisted acid cleavage Covalent bonds form between the sulfuratoms and the metal radionuclide. A separate step for removal of thesulfur-protective groups is not necessary. The radiolabeling procedurethus is simplified. In addition, the basic pH conditions and harshconditions associated with certain known radiolabeling procedures orprocedures for removal of other sulfur protective groups are avoided.Thus, base-sensitive groups on the chelating compound survive theradiolabeling step intact. Such base labile groups include any groupwhich may be destroyed, hydrolyzed, or otherwise adversely affected byexposure to basic pH. In general, such groups include esters,maleimides, and isothiocyanates, among others. Such groups may bepresent on the chelating compound as conjugation groups.

The aromatic ring atoms designated as X, Y, X′ and Y′ are independentlyselected from carbon, nitrogen, sulfur and oxygen to independently formfive or six member rings, wherein the remaining ring atoms are carbon.The aromatic rings containing X and Y or X′ and Y′ are selectedindependently. For example, one ring may be a five member ring and theother a six member ring. For six member rings, where X, Y, X′ and Y′ areall carbon, the aromatic rings are benzene type rings. Where X, Y, X′and Y′ are all nitrogen, the aromatic rings are pyrimidine type ringsWhere one of X or Y and one of X′ or Y′ are nitrogen, the aromatic ringsare pyridine type rings.

For five member rings where X, Y, X′ and Y′ are all nitrogen, thearomatic rings are imidazole or pyrazole type rings. Where one of X or Yand one of X′ or Y′ are sulfur, the aromatic rings are thiophene typerings. Where one of X or Y and one of X′ or Y′ are sulfur and nitrogen,the aromatic rings are thiazole or isothiazole type rings, where on of Xor Y and one of X′ or Y′ are oxygen, the aromatic rings are furan typerings, where one of X or Y and one of X′ or Y′ are oxygen and nitrogen,the aromatic rings are oxazole or isoxazole type rings.

Preferred embodiments of the aromatic rings designated X, Y, X′ and Y′include benzene, pyrimidine, pyridine and thiophene, the most preferredbeing benzene or thiophene. These particular aromatic rings areinterchangeable within the chelating compound formula because they areeither structurally related or contribute similar properties, e.g.,spatial configuration, electronic resonance and inductive properties(i.e., electron withdrawing and donating effects).

The chelation compounds and metal chelates of the present invention mayalso be asymmetric with respect to the nature of the aromatic rings. Forexample, the aromatic rings are a combination of benzene and pyridinetypes where X and Y are both carbon and either X′ or Y′ are both carbon,or either X or Y is nitrogen and X′ and Y′ is nitrogen, or either X or Yis nitrogen and X′ and Y′ are both carbon. In another embodiment, thearomatic rings are a combination of benzene and pyrimidine types where Xand Y are both carbon and X′ and Y′ are both nitrogen, or X and Y areboth nitrogen and X′ and Y′ are both carbon. In another embodiment, thearomatic rings are a combination of pyridine and pyrimidine types whereeither X or Y is nitrogen and X′ and Y′ are both nitrogen, or X and Yare both nitrogen and either X′ or Y′ are nitrogen. In anotherembodiment, the aromatic rings are a combination of benzene andthiophene types where either X or Y are both carbon and either X′ or Y′is sulfur, or either X or Y is sulfur and X′ and Y′ are both carbon. Inanother embodiment, the aromatic rings are a combination of pyridine andthiophene types whether either X or Y is nitrogen and one of which iscarbon and X′ or Y′ is sulfur and one of which is carbon, or either X orY is sulfur, one of which is carbon and either X′ or Y′ is nitrogen, oneof which is carbon. Further variations of the aromatic rings of thepresently identified chelation compounds will be evident to one ofordinary skill in the based on the present disclosure in view of theart.

As noted above, in addition to providing chelation compounds, thepresent invention provides radionuclide metal chelate compounds whereina metal is chelated (complexed) The chelation compounds of the presentinvention rapidly form stable metal complexes (radionuclide metalchelates) when reacted with a metal.

The preferred radionuclide metal chelate compound (complexes) of thepresent invention have the formula (II):

wherein R₁-R₁₁, n, X, X′, Y, Y′ are described above. A and A′ may beindependently selected from nitrogen, sulfur and oxygen. M is aradiometal or a radionuclide metal oxide or nitride, capable of beingchelated by a compound of the present invention. Preferred metals andmetal oxides or nitrides include radionuclides of copper, yttrium,ruthenium, technetium, rhodium, palladium, gadolinium, samarium,holmium, ytterbium, lutetium, indium, rhenium, gold, lead and bismuth.Particularly preferred are ⁶⁴Cu, ⁶⁷Cu, ⁹⁰Y, ⁹⁷Ru, ^(99m)Tc, ¹⁰⁵Rh,¹⁰⁹Pd, ¹¹¹In, ¹⁵³Sm, ¹⁵⁹Gd, ¹⁶⁶Ho, ¹⁷⁵Yb, ¹⁷⁷Lu, ¹⁸⁶Re, ¹⁸⁸Re, ¹⁹⁸Au,¹⁹⁹Au, ²⁰³Pb, ²¹²Pb and ²¹²Bi.

Methods for preparing these isotopes are known Molybdenum/technetiumgenerators for producing ^(99m)Tc are commercially available. Proceduresfor producing ¹⁸⁶Re include the procedures described by Deutsch et al.(Nucl. Med. Biol. 13(4):465-477, 1986) and Vanderheyden et al.(Inorganic Chemistry 24:1666-1673, 1985) (see also U.S. Pat. No.5,053,186), and methods for production of ¹⁸⁸Re have been described byBlachot et al. (Intl. J. of Applied Radiation and Isotopes 20:467-470,1969) and by Klofutar et al. (J. of Radioanalytical Chem. 5:3-10, 1970)(see also U.S. Pat. No. 4,859,431). Production of ¹⁰⁹Pd is described inFawwaz et al. (J. Nucl. Med. 25:786, 1984). Production of ²¹²Pb and²¹²Bi is described in Gansow et al. (Amer. Chemi Soc. Symp. Ser241:215-217, 1984) and Kozah et al. (Proc. Natl. Acad. Sci. USA83:474-478, 1986). Production of ⁹⁰Y, a particle emitting therapeuticradionuclide resulting from transmutation processes (withoutnon-radioactive carrier forms present), is commercially available fromseveral sources, including Pacific Northwest National Laboratory,located in Richland, Wash.; Nordion International Inc., located inKanata, Ontario, Canada and by Du Pont as NEN Research products locatedin North Billerica, Mass. Production of ¹⁵³Sm is described in Goeckeleret al (Nucl. Med. Biol, Vol. 20, No. 5, pp. 657-661, 1993). ¹¹¹In iscommercially available as INDICLOR™ supplied by Amersham Healthcarelocated in Arlington Heights, Ill. ^(99m)Tc is preferred for diagnosticuse, and the other radionuclides listed above are preferred fortherapeutic use.

In one embodiment of the present invention, chelation compounds of theinvention including acetamidomethyl and/or hemithioacetal sulfurprotective groups are radiolabeled with a metal radionuclide by reactingthe compound with the radionuclide under conditions of acidic pH. It isbelieved that the acidic pH and the presence of the metal bothcontribute to the displacement of the sulfur protective groups from thechelating compound. The radionuclide is in chelatable form when reactedwith the chelation compounds of the invention.

In the case of technetium and rhenium being in “chelatable form”generally requires a reducing step. A reducing agent will be employed toreduce the radionuclides (e.g., in the form of pertechnetate andperrhenate, respectively) to a lower oxidation state at which chelationwill occur. Many suitable reducing agents, and the use thereof, areknown . (See, for example, U.S. Pat. Nos. 4,440,738; 4,434,151; and4,652,440.) Such reducing agents include stannous ion (e.g., in the formof stannous salts such as stannous chloride or stannous fluoride),metallic tin, ferrous ion (e.g., in the form of ferrous salts such asferrous chloride, ferrous sulfate, or ferrous ascorbate) and manyothers. Sodium pertechnetate (i.e., ^(9m)TcO₄ ⁻¹ which is in the +7oxidation level) or sodium perrhenate (i.e., ¹⁸⁸ReO₄ ⁻¹, ¹⁸⁶ReO₄ ⁻¹) maybe combined simultaneously with a reducing agent and a chelatingcompound of the invention, in accordance with the radiolabeling methodof the invention, to form a chelate.

Preferably, the radionuclide is treated with a reducing agent and acomplexing agent to form an intermediate complex (i.e., an “exchangecomplex”). Complexing agents are compounds which bind the radionuclidemore weakly than do the chelate compounds of the invention, and may beweak chelators. Any of the suitable known complexing agents may be used,including gluconic acid, glucoheptonic acid, tontanic acid, methylenedisphosphonate, glyceric acid, glycolic acid, mannitol, oxalic acid,malonic acid, succinic acid, bicine, N,N′-bis(2-hydroxy ethyl) ethylenediamine, citric acid, ascorbic acid and gentisic acid. Good results areobtained using gluconic acid or glucoheptonic acid as the Tc-complexingagent and citric acid for rhenium. When the radionuclide in the form ofsuch an exchange complex is reacted with the chelation compounds of theinvention, the radionuclide will transfer to the chelation compounds,which bind the radionuclide more strongly to form chelates of theinvention. In some instances, heating is necessary to promote transferof the radionuclide. Radionuclides in the form of such complexes alsoare considered to be in “chelatable form” for the purposes of thepresent invention.

Y-90 is a particularly preferred radionuclide for therapy, because itexhibits favorable nuclear properties including high specific activity,long path length with respect to deposition of radiation in tissue, highequilibrium dose constant and favorable half-life properties. Morespecifically, the beta emission of Y-90 (Beta_(av)=0.937 MeV) makes itone of the most energetic of all beta emitters. The X₉₀ value of Y-90 is5.34 mm (i.e., 90% of the energy emitted from a point source is absorbedin a sphere of 5.34 mm radius). Y-90 has a high equilibrium doseconstant or mean energy/nuclear transition, Delta=1.99Rad-gram/microcurie-hour, and a 64 hour half-life suitable for targetedtherapy. Y-90 can be manufactured at high specific activity and isavailable as a generator product. Specific advantages of Y-90 are (1)that it has the capability to kill neighboring target cells not directlytargeted by conventional methods (2) that more radiation is depositedper microcurie localized than for other beta emitters of lower meanparticle energy (provided that a sufficiently large target volume isavailable).

Chelates of ²¹²Pb, ²¹²Bi, ¹⁰⁹Pd, Cu⁶⁴ and Cu⁶⁷ may be prepared bycombining the appropriate salt of the radionuclide with the chelatingcompound and incubating the reaction mixture at room temperature or athigher temperatures. It is not necessary to treat the lead, bismuth,palladium and copper radioisotopes with a reducing agent prior tochelation, as such isotopes are already in an oxidation state suitablefor chelation (i.e., in chelatable form). The specific radiolabelingreaction conditions may vary somewhat according to the particularradionuclide and chelating compound involved.

In another embodiment of the present invention, where the sulfurs areprotected by formation of a disulfide bond, chelation compounds of theinvention are radiolabeled following reduction of the disulfide bondunder mild conditions. For example, the disulfide may be reduced withSnCl₂ under conditions which do not reduce disulfides on proteins suchas antibodies.

The chelation compounds and metal chelates of the present invention havea variety of uses, although certain uses are preferred depending uponthe particular embodiment. In one embodiment of the present invention,the chelation compounds can be employed in the pretargeting methods asdescribed in U.S. Pat. No. 5,608,060.

In another embodiment of the present invention, the chelation compoundsand the radionuclide metal chelates are either reactive with a targetingmoiety, or are conjugated to a targeting moiety. These compounds may begenerally represented by the above-described compounds which bear thegroup Z. A chelating compound or a metal chelate that is reactive with atargeting moiety bears at least one conjugation group Z. Suchconjugation groups include those described above (e.g., an active esteror a maleimide). Alternatively, the chelating compound or metal chelatemay be conjugated to a targeting moiety Z. Such targeting moietiesinclude those described above (e.g., proteins and antibodies). Thepreparation of representative chelation compounds that are reactive withtargeting moieties is presented in the examples below. The preparationof representative radionuclide metal-targeting moiety conjugates is alsopresented in the examples below.

In the practice of the present invention, metal chelate-targeting moietyconjugates may be prepared by complexation of the radionuclide metaleither before or after the chelating compound is conjugated to thetargeting moiety. More specifically, a conjugate may be “pre-formed” or“post-formed,” depending upon whether the chelating compound andtargeting moiety are joined after or before the complexation of theradionuclide metal. A pre-formed conjugate comprises a chelatingcompound of the present invention that is first labeled with aradionuclide metal and then is conjugated to a targeting moiety. Apost-formed conjugate comprises a chelating compound of the presentinvention that is first conjugated to a targeting moiety and then islabeled with a radionuclide metal. Thus, for pre-formed conjugates, theradionuclide is added to the chelating compound prior to the addition ofthe targeting moiety, whereas, for post-formed conjugates, theradionuclide is added after the addition of the targeting moiety. Thefinal conjugate is the same regardless of how formed.

Generally, the chelation compounds of the present invention that areeither reactive with targeting moieties or are conjugated to targetingmoieties may be represented by the formula (I) above, where the specificembodiments of the elements of the formula include the following:

-   -   R₁ and R₂ may be independently hydrogen (H), an oxy group (═O);        or —(CH₂)_(m)-Z where m is 0-10 and Z represents a conjugation        group or targeting moiety; or R₁ and R₂ may be taken together to        form a cyclic anhydride or a benzene ring.

The distance between the chelating nitrogen atoms of formula (I) may bevaried by the imposition of a methylene group. When imposed, themethylene group may be substituted with R₃.

R₃ may be hydrogen, a lower alkyl group, an alkoxy group, a halogen, ahydroxyl group, a nitro group, or —(CH₂)_(m)-Z.

R₄ and R₅ may be attached at one or more of the aromatic ring positions,preferably the ring carbon atoms, and are independently selected fromhydrogen, a lower alkyl group, an alkoxy group, a halogen, a hydroxylgroup, a nitro group, and —(CH₂)_(m)-Z.

R₆ and R₇ are independently selected from lower alkyl, alkoxy, halogen,hydroxyl, nitro, —(CH₂)_(m)-Z, and

where Q represents multivalent acid functionality capable ofcoordinating with metal ions, and m=0 to 1; R₁₂ and R₁₃ areindependently selected from hydrogen, hydroxyl, carboxyl, phosphonic,and hydrocarbon radicals having from 1-10 carbon atoms, andphysiologically acceptable salts of the acid radicals, and R₁₂ and R₁₃may be the same as or different from one another.

The chelation compounds reactive with or conjugated to targetingmoieties have at least one Z, but may contain more than one Z. Forexample, any two groups selected from R₁-R₅ may be Z.

A, A′, X, X′, Y, Y′ and n are as described above for formula (I).

Similarly, the radionuclide metal chelate compounds of the presentinvention that are either reactive with targeting moieties or areconjugated to targeting moieties may be represented by the formula (II).The specific embodiments of those elements of the formula denoted byR₁-R₅, n, X, X′, Y, and Y′ are as described immediately above for thechelation compounds. M is a radionuclide, radionuclide metal oxide orradionuclide metal nitride. The metal chelate compounds reactive with orconjugated to targeting moieties have at least one Z, but may containmore than one Z.

In a preferred embodiment, the compounds of the present invention are“N₄” (N₄S₀O₀) chelation compounds and metal chelates. Therefore, forpreferred chelation compounds and metal chelates, A and A′ are nitrogen.For particularly preferred chelation compounds, A and A′ are nitrogenatoms joined together by a bond, i.e., R₁₀ and R₁₁ form T, the chelationcompounds are tetraazacyclic, a tetradectane system. Preferred compoundsof the present invention have X, Y, X′ and Y′ as carbon, nitrogen andsulfur. For the metal chelates of the present invention, technetium(e.g., ^(99m)Tc) and indium (e.g., ¹¹¹In) are the preferred metals fordiagnostic purposes, and rhenium (e.g., ¹⁸⁶Re and ¹⁸⁸Re) and yttrium(e.g., ⁹⁰Y) are the preferred metals for therapeutic purposes.

Further, in a preferred embodiment, the compounds of the presentinvention, which are reactive with targeting moieties, possess a singleconjugation group. A preferred conjugation group is theN-hydroxysuccinimide ester group.

In a preferred embodiment, in addition to the above-mentionedpreferences, the conjugation group is an aromatic ring substituent,i.e., either R₄ or R₅ is —(CH₂)_(m)-Z. For one such preferredembodiment, n=1, R₁-R₄ are hydrogen, and R₅ is —(CH₂)_(m)-Z, where m=0and Z is an active ester such as an N-hydroxysuccinimide ester.Alternatively, the conjugation group may be a substituent of the carbonslinking the chelating nitrogens, i.e., R₁-R₃. In one such preferredembodiment, n=1, R₁ or R₂ are —(CH₂)_(m)-Z where m=0 and Z is anN-hydroxysuccinimide ester, R₃ is hydrogen, and R₄ and R₅ are hydrogen.In another such preferred embodiment, n=1, R₁ and R₂ are hydrogen, R₃ is—(CH₂)_(m)-Z as described immediately above, and R₄ and R₅ are hydrogen.R₆, R₇, R₈ and R₉ may be

where Q represents multivalent acid functionality capable ofcoordinating with metal ions, and m=0 to 1; R₁₂ and R₁₃ areindependently selected from hydrogen, hydroxyl, carboxyl, phosphonic,and hydrocarbon radicals having from 1-10 carbon atoms, andphysiologically acceptable salts of the acid radicals, and R₁₂ and R₁₃may be the same as or different from one another.

In another preferred embodiment, in the “N₄” (N₄S₀O₀) compounds of thepresent invention the conjugation group is an anhydride, i.e., R₈ andR₁₀ and R₉ and R₁₁ are taken together in a vicinyl configuration, toform a cyclic anhydride, —(CH₂)_(m)-Z where m=1 and Z is a carboxylicacid anhydride resulting from vicinyl dicarboxylic acids. In one suchembodiment, in addition to the above-mentioned preferences, R₁-R₅ arehydrogen, n=1, R₆ and R₇ are

where Q represents multivalent acid functionality capable ofcoordinating with metal ions, and p=0 to 1; R₁₂ and R₁₃ areindependently selected from hydrogen, hydroxyl, carboxyl, phosphonic,and hydrocarbon radicals having from 1-10 carbon atoms, andphysiologically acceptable salts of the acid radicals, and R₁₂ andR₁₃may be the same as or different from one another.

In another preferred embodiment, the conjugation group is an anhydride,i.e., R₁ and R₂ are taken together to form a cyclic anhydride. In onesuch embodiment, in addition to the above-mentioned preferences, R₁ andR₂ are taken together to form a cyclic anhydride, n=0, and R₄ and R₅ arefluorine.

For the compounds of the present invention which are conjugated totargeting moieties, preferred targeting moieties include proteins suchas antibodies and annexin as well as binding proteins such as avidin andstreptavidin.

In another aspect of the present invention, the chelation compounds andthe radionuclide metal chelate compounds are used in radiopharmaceuticalapplications without the necessity for a conjugation group or targetingmoiety. Such chelating and metal chelate compounds are useful by virtueof their lipophilic properties and may be generally represented by theabove-described compounds which bear hydrolyzable group W.

Generally, the chelation compounds of the present invention that areuseful without possessing a conjugating group or targeting moiety may berepresented by the formula (I) above where the specific embodiments ofthe elements of the formula include the following.

R₁ and R₂ may be independently hydrogen (H), an oxy group (═O); or—(CH₂)_(m)—W where W represents a hydrolyzable group; or R₁ and R₂ maybe taken together to form a cyclic anhydride or benzene ring.

The distance between the chelating nitrogen atoms of formula (I) may bevaried the imposition of a methylene group, —CH₂. When imposed, themethylene group may be substituted with R₃.

R₃ may be hydrogen, a lower alkyl group, an alkoxy group, a halogen, ahydroxyl group, a nitro group, and —(CH₂)_(m)—W

R₄ and R₅ may be attached at one or more of the aromatic ring positions,preferably the ring carbon atoms, and are independently selected fromhydrogen, a lower alkyl group, an alkoxy group, a halogen, a hydroxylgroup, a nitro group, or —(CH₂)_(m)—W.

The chelation compounds that are useful in the absence of a conjugationgroup of targeting moiety have at least one W, but may contain more thanone W. For example, any two groups selected from R₁-R₅ may be W.

A, A′, X, X′, Y, Y′, R₆, R₇, and R₈ through R₁₁ and n are as describedabove for formula (I).

Similarly, the radionuclide metal chelate compounds of the presentinvention that are useful without a conjugation group or targetingmoiety may be represented by the formula (II) where the specificembodiments of the elements of the formula, R₁-R₅, R₆-R₁₁, n, X, X′, Yand Y′ are as described immediately above for the chelation compounds. Mis a radionuclide, radionuclide metal oxide or radionuclide metalnitride. The metal chelates that are useful in the absence of aconjugation group or targeting moiety have at least one W, but maycontain more than one W.

In a preferred embodiment, W is an enzyme hydrolyzable group, such as anester or a carbamate Such groups are subject to hydrolysis by esterasescommonly found in tissues such as the heart and bone marrow In aparticularly preferred embodiment, the hydrolyzable group is an ethylester or ethyl carbamate.

Preferred embodiments of the compounds which possess hydrolyzable groupsW include the preferences for M, A, A′, X, Y, X′ and Y′ described abovefor the compounds which possess a conjugation group or a targetingmoiety, Z. In a preferred embodiment, the compounds of the presentinvention having hydrolyzable groups W possess more than one W.

In one preferred embodiment, in addition to the above-mentionedpreferences, the hydrolyzable group is an aromatic ring substituent,i.e., R₄ and R₅ are —(CH₂)_(m)—W. For one such embodiment, n=1, R₁-R₃are hydrogen, and R₄ and R₅ are —(CH₂)_(m)—W, where m=0 and W is eitheran ester (i e., —CO₂Et), a carbamate (i.e., —NH—CO₂Et) or a nitrile(—CN) Alternatively, in another preferred embodiment, where both R₄ andR₅ are —(CH₂)_(m)—W as described immediately above, n=1, either R₁ or R₂is an oxy group (═O) and R₃ is either hydrogen or —(CH₂)_(m)—W.

In another preferred embodiment, the hydrolyzable group W is asubstituent of the carbon atoms linking the chelating nitrogens, i.e.,one or more of R₁-R₃ is —(CH₂)_(m)—W. For example, in one such preferredembodiment, in addition to the above noted preference, n=0, R₁ and R₂are —(CH₂)_(m)—W where m=0 and W is an ester, and R₄ and R₅ arefluorine. In another such preferred embodiment, n=1, either R₁ or R₂ isan oxy group (═O), R₃ is —(CH₂)_(m)—W as described immediately above,and R₄ and R₅ are methyl. In a further such preferred embodiment, n=1,R₁ and R₂ are hydrogen, R₃ is —(CH₂)_(m)—W as described above, and R₄and R₅ are methoxy.

The lipophilic properties of these chelating and metal chelate compoundsare due in part to the hydrophobic nature of hydrolyzable W. As notedabove, W includes any neutral organic group that provides a chargedgroup upon hydrolysis. Generally, the neutral organic group of W ishydrophobic and imparts lipophilic character to the chelating and metalchelate compounds.

The lipophilic compounds of the present invention are particularlyuseful in vivo where it is desirous to accumulate the metal chelates intissues such as the heart and bone marrow. In such applications, theadministered lipophilic metal chelates reach these tissues through thebloodstream and, because of their lipophilic properties, the metalchelates are absorbed by these tissues. Once absorbed into the tissues,the metal chelates are subject to hydrolysis where the hydrolyzablegroup, W (e.g., an ester), which imparted lipophilicity to the chelateis converted to a charged species (e.g., an acid if the ester is acarboxylate ester, and a base if the ester is a carbamate ester) and isthereby prevented from escaping the tissue.

Suitable hydrolyzable groups W included nitrites, carbamates, andesters. Preferred hydrolyzable groups include carbamates and carboxylateesters. Preferred carboxylate esters include methyl, ethyl, propyl andisopropyl esters. Preferred carbamate esters include methyl and ethylesters.

The lipophilic metal chelates of the present invention, which bearhydrolyzable groups W, may undergo either chemical or enzymatichydrolysis to yield residually charged metal chelates. To be effective,the metal chelates are resistant to rapid hydrolysis in the bloodstream,but are readily hydrolyzed upon uptake by the tissue of interest.Hydrolysis which occurs in the bloodstream is primarily chemical innature while tissue hydrolysis is primarily enzymatic.

In one embodiment, the compounds of the present invention areadditionally resistant toward chemical hydrolysis. For example, thechelation compounds and metal chelates that bear ester groups, which aredirectly conjugated to the aromatic ring as either ortho or parasubstituents relative to the chelating nitrogen, are particularly stabletoward chemical hydrolysis. Referring to the above formulas, thesepreferred compounds are represented by those compounds where R₄ and/orR₅ are —(CH₂)_(m)—W (m=0 and W is an ester), and where R₄ and/or R₅ islocated ortho or para to the chelating nitrogen.

Such suitably substituted esters are resistant toward chemicalhydrolysis by virtue of electron donation from the chelating nitrogenthrough the aromatic ring to the ester carbonyl group. This dispersal ofelectron density renders the ester carbonyl relatively electron rich andreduces its reactivity as an electrophile. Because the rate-determiningstep in ester hydrolysis is the addition of a nucleophilic watermolecule to the ester carbonyl, ester carbonyl groups that are lesselectrophilic react more slowly toward nucleophilic addition. Thus,ester carbonyl groups which are stabilized toward nucleophilic additionby electron donating groups are resistant toward hydrolysis For thesereasons, the above-described esters of the present invention areresistant toward chemical hydrolysis in the bloodstream.

While the efficacy of the administration of the lipophilic compounds ofthe present invention resides in part in their stability towardhydrolysis in the bloodstream, their ultimate utility asradiopharmaceutical agents relies on their capacity to be taken up andretained by various tissues. The uptake of these compounds into thetissue results from the particular character of the compounds and thepermeability of the tissues toward such compounds.

The compounds of the present invention are retained within a tissue,such as malignant cells, by conversion of the lipophilic compounds tocharged compounds (ionic species) by hydrolysis. The compounds of thepresent invention, which are resistant to chemical hydrolysis, arereadily susceptible to enzymatic hydrolysis. Suitable hydrolyzablegroups that are converted to charged compounds by enzymatic actioninclude ester and carbamate groups which are converted to carboxylicacid and amino groups, respectively.

The compounds of the present invention may be taken up by varioustissues, but are primarily intended for the tissues containing malignantcells and activated platelets. The metal chelates of the presentinvention may be selectively taken up by either malignant cell tissuedepending upon the nature of the chelate.

The radiolabeled chelates of the present invention have use indiagnostic and therapeutic procedures, both for in vitro assays and forin vivo medical procedures. The radiolabeled chelates may be delivered(e.g., administered to a warm-blooded animal such as a human)intravenously, intraperitoneally, intralymphatically, locally, or byother suitable means, depending on such factors as the type of targetsite. The amount to be provided will vary according to such factors asthe type of radionuclide (e.g., whether it is a diagnostic ortherapeutic radionuclide), the route of delivery, the type of targetsite(s), the affinity of the targeting moiety, if employed, for thetarget site of interest, and any cross-reactivity of the targetingmoiety, if employed, with normal tissues. Appropriate amounts may beestablished by conventional procedures, and a physician skilled in thefield to which this invention pertains will be able to determine asuitable amount for a patient. A diagnostically effective dosage isgenerally from about 5 to about 35 and typically from about 10 to about30 mCi per 70 kg body weight. A therapeutically effective dosage isgenerally from about 20 mCi to about 300 mCi or higher. For diagnosis,conventional non-invasive procedures (e.g., gamma cameras) are used todetect the biodistribution of the diagnostic radionuclide, therebydetermining the presence or absences of the target sites of interest(e.g., tumors, heart, brain).

The comparatively low intestinal localization of the therapeuticradiolabeled chelates of the present invention or catabolites thereofpermits increased dosages, since intestinal tissues are exposed to lessradiation. The clarity and accuracy of diagnostic images also isimproved by the reduced localization of radiolabeled chelates orcatabolites thereof in normal tissues via an increase in target tonontarget ratio.

The invention is further described through presentation of the followingexamples. These examples are offered by way of illustration and not byway of limitation.

EXAMPLES Example I N,N′-Bis(2-diaminophenyl)-1,3-propyldiaminohexaacetic acid 5

N,N′-Bis(2-dinitrophenyl)-1,3-propyldiamine 2

A stirred suspension of 30.0 g (0.217 mole) of 2-nitroaniline 1, 5.0 mL(0.044 mole) of 1,3-diiodopropane and 1.90 g (0.023 mole) of sodiumbicarbonate in 100 mL xylene was heated at 140-145° C. for 36 hours. Thereaction mixture was cooled down in an ice bath. The precipitate wascollected by filtration. The red solid was washed several times withcold heptane to remove excess unreacted 2-nitroaniline 1 and 2-nitroN-methylaniline. The crude product was purified by flash chromatographyon a silica gel column using 20% ethyl acetate in hexane as an elutionsolvent. After 2-nitro-aniline and 2-nitro N-methylaniline were removedfrom this solvent system, the desired product was then eluted from thecolumn using 50% ethyl acetate in hexane. The fractions containing theproduct were combined. Solvent was removed under reduced pressure anddried to yield 10.30 g (15%) of compound 2.

N,N′-Bis(2-diaminophenyl)-1,3-propane-diamine 3

1.0 g (0.003 mole) of N,N′-Bis(2-dinitrophenyl)-1,3-propyldiamine 2 wastaken into a parr hydrogenation bottle. 200 mL of 2% glacial acetic acidin absolute ethanol was added. To the suspension, 0.2 g of 10% palladiumon activated carbon was added. The reaction mixture was catalyticallyreduced under hydrogen atmosphere at 40 PSI for 4-6 hours. The solutionwas filtered and the solvent was removed under reduced pressure anddried. The crude residue was placed in a sodium bicarbonate solution,and the free amine was extracted into methylene chloride three times,each time with 100 mL volume. The combined organic layer was dried overanhydrous sodium sulfate and filtered. Solvent was removed under reducedpressure and dried to yield crude residue The crude residue was purifiedby silica gel column chromatography using 50% ethyl acetate in hexane asan elution solvent The fractions containing the desired product werecombined. Solvent was removed under reduced pressure and dried to yield0.53 g (65%) of compound 3.

N,N′-Bis(2-diaminophenyl)-1,3-propane diaminohexacetic acid 4

To a stirred suspension of 5.0 g (0.020 mole) of N,N′-Bis(2-diaminophenyl)-1,3-propanediamine 3 in 75 mL of distilled water, 20.0g (0.143 mole) of bromoacetic acid is added and magnetically stirred.The pH of the solution is adjusted to 10.0 with 2.0 N sodium hydroxideand the reaction mixture is heated in an oil bath at 45° C. for 16 hoursThe pH is maintained between 9.75 and 10.0 with 5.0 N sodium hydroxideduring the entire course of reaction. The progress of the reaction ismonitored by high performance liquid chromatography (HPLC) usingPRP-X100 anion exchange column (supplied by Hamilton). Small amounts ofbromoacetic acid (i.e., 100 to 200 mg) are added to the reaction mixtureto drive the reaction to completion. The reaction mixture is dilutedwith sterile water to 2 liter volume and the pH is adjusted to 6.8 with6.0 N hydrochloric acid. The conductivity for this solution is 4.89ms/cm. It is further diluted to 4 liters with sterile water and the pHis adjusted to 8.2 with 2.0 N sodium hydroxide. The measuredconductivity is 2.89 ms/cm. This solution is loaded on a 5×60 cm columnwith 900 mL bed volume of AG® 1-X2 (Bio-Rad Laboratories, Richmond,Calif.) (acetate form) resin which is prewashed with 1 liter 1.5 Macetic acid, 1.5 liter water, 0.5 liter 0.02 N ammonium acetate pH 7.18and 4 liter water final eluent pH 4.28 by fast performance liquidchromatography (FPLC) at 40 mL/min. The column is eluted with water andgradually increased the solvent B (1.50 M acetic acid) of the gradientsystem. Fractions containing the product are pooled and solventevaporated and dried under high vacuum to give 6.75 g (57%) of compound4.

N,N′-Bis(2-diaminophenyl)-1,3-propane-diamino hexamethylene phosphonicacid 5

25.0 g (0.31 mole) of phosphorous acid and 25 mL of degassed water aretaken into a 3 neck round bottom flask equipped with a dropping funnel,a thermometer and a magnetically stirring bar. The flask is flushed withnitrogen gas and a slow stream of nitrogen is maintained in the flask.Dissolution of the phosphorous acid is achieved upon stirring. 30 mL ofconcentrated hydrochloric acid is added to the reaction mixture and thestirring continued. The dropping funnel is charged with 20.0 g (0.078mole) of N,N′-bis(2-diaminophenyl)-1,3-propanediamine dissolved in 25 mLwater. The amine solution from the dropping funnel is added dropwise tothe stirred acidic solution under nitrogen atmosphere After completionof addition, the reaction mixture is heated under reflux using an oilbath for at least 1.0 hour. Then the dropping funnel is charged withformaldehyde 27.2 g (0.938 mole) of a 37% aqueous solution and is addedto the reaction mixture dropwise over a 2 to 3 hour time interval. Thereaction mixture is continued heating under reflux throughout the entireformaldehyde solution addition period. After completion of all of theformaldehyde solution, the reaction mixture is continued stirring underreflux for an additional 3 to 4 hours. The reaction mixture is thenallowed to cool and the productN,N′-Bis(2-diaminophenyl)-1,3-propane-diamino hexamethylene phosphonicacid is isolated from the reaction mixture and purified by ion exchangeresin chromatography.

Example II 2,3,9,10-diphenylenyl-1,4,8,11 -tetraazacyclotetradecane-N,N′,N″,N″′-tetraacetic acid 7 and2,3,9,10-diphenylenyl-1,4,8,11-tetraazacyclotetradecane-N,N′,N″,N″′-tetramethylene phosphonic acid 8

2,3,9,10-diphenylenyl-1,4,8,11-tetraazacyclo tetradecane 6

A stirred solution of 10.0 g (0.039 mole) ofN,N′-Bis(2-diaminophenyl)-1,3-propane-diamine 3, 2.30 g (0.008 mole) of1,3-diiodopropane and 6.50 g (0.08 mole) of sodium bicarbonate in 100 mLdry dimethyl sulfoxide is heated at 115° C. for 4 hours under nitrogenatmosphere. The dimethyl sulfoxide solvent is removed under high vacuumand dried. The crude product is extracted three times each time with 100mL methylene chloride by partitioning with water. The combined methylenechloride layer is washed with brine and water. The organic layer isdried over anhydrous sodium sulfate and filtered. Solvent from thefiltrate is removed under reduced pressure to yield crude product. Thecrude residue is purified by flash chromatography on silica gel columnusing 25% ethyl acetate in hexane as an elution solvent. The fractionscontaining the product are combined and the solvent removed underreduced pressure and dried to yield 1.20 g (10%) of compound 6.

2,3,9,10-diphenylenyl-1,4,8,11-tetraazacyclotetradecane-N,N′,N″,N″′-tetraacetic acid 7:

To a stirred suspension of 10.0 g (0.034 mole) of 6 in 200 mL distilledwater, 40.0 g (0.288 mole) of bromoacetic acid is added. The reactionmixture is stirred magnetically at room temperature. The pH of thesolution is adjusted to 10.0 with 2.0 N sodium hydroxide and thereaction mixture is heated in an oil bath at 45° C. for 16 hours The pHis maintained between 9.75 and 10.0 with 5.0 N sodium hydroxide duringthe entire course of reaction. The progress of the reaction is monitoredby HPLC using PRP-X100 anion exchange column and small amounts ofbromoacetic acid is added to the reaction mixture to drive the reactionto completion. The reaction mixture is diluted with sterile water to 2liter volume and the pH is adjusted to 6.8 with 6.0 N hydrochloric acid.The conductivity for this solution is 4.89 ms/cm. It is further dilutedto 4 liters with sterile water and the pH is adjusted to 8.2 with 2.0 Nsodium hydroxide. The measured conductivity is 2.89 ms/cm. This solutionis loaded on 5×60 cm column with 900 mL bed volume of AG® 1-X2 (acetateform) resin which is prewashed with 1 liter 1.5 M acetic acid, 1.5 literwater, 0.5 liter 0.02 N ammonium acetate pH 7.18 and 4 liter water finaleluent pH 4.28 by FPLC at 40 mL/min. The column is eluted with water andgradually increased the solvent B (1.50 M acetic acid) of the gradientsystem. Fractions containing the product are pooled and solventevaporated and dried under high vacuum to give 7.10 g (40%) of compound7.

2,3,9,10-diphenylenyl-1,4,8,11-tetraazacyclotetradecane-N,N′,N″,N″′-tetramethylene phosphonic acid 8

5.0 g (0.061 mole) of phosphorous acid and 10 mL of degassed water aretaken into a 3 neck round bottom flask equipped with a dropping funnel,a thermometer and a stir bar. The flask is flushed with nitrogen gas anda slow stream of nitrogen is maintained in the flask. Dissolution of thephosphorous acid is achieved upon stirring. 8.0 mL of concentratedhydrochloric acid is added to the reaction mixture and the stirringcontinued. The dropping funnel is charged with 4.0 g (0.014 mole) of2,3,9,10-diphenylenyl-1,4,8,11-tetraazacyclo tetradecane, 6 dissolved in10 mL water. The cyclic amine solution from the dropping funnel is addeddropwise to the stirred acidic solution under nitrogen atmosphere Aftercompletion of addition, the reaction mixture is heated under refluxusing an oil bath for at least 1 hour. Then the dropping funnel ischarged with formaldehyde 5.0 g (0.172 mole) of a 37% aqueous solutionand is added to the reaction mixture dropwise over a 2 to 3 hour timeperiod. The reaction mixture is continued heating under refluxthroughout the entire formaldehyde solution addition. After completionof all of the formaldehyde solution, the reaction mixture is continuedstirring under reflux for an additional 3 to 4 hours. The reactionmixture is then allowed to cool and the product2,3,9,10-diphenylenyl-1,4,8,11-tetraazacyclotetradecane-N,N′,N″,N″′-tetramethylene phosphonic acid 8 is isolatedfrom the reaction mixture and purified by ion exchange chromatography in35% yield.

Example III 2,3,8,9,-diphenylenyl 5,6,11,12 -bis orthocarboxydiphenylenyl-1,4,7,10 -tetraazacyclododecaneN,N′,N″,N″′-tetraacetic acid 13 and 2,3,8,9-diphenylenyl 5,6,11,12-bisortho carboxydiphenylenyl-1,4,7,10-tetraazacyclododecaneN,N′,N″,N″′-tetramethylene Phosphonic Acid 14

N-Phenyl N-(1-chloro 3-carboxyphenyl)amine 9

To a stirred solution of 20.0 g (0.145 mole) of 2-nitroaniline 1, 28.0 g(0.146 mole) of 2,3-dichlorobenzoic acid in 200 mL dry dimethylsulfoxide, 20.0 g (0.19 mole) of anhydrous sodium carbonate is added.The reaction mixture is heated at 110° C. for 5 hours under nitrogenatmosphere. The dimethyl sulfoxide solvent from the reaction mixture isremoved under high vacuum and dried. The crude product is extractedthree times each time with 100 mL methylene chloride by partitioninginto water. The combined methylene chloride layer is dried overanhydrous sodium sulfate and filtered. Solvent from the filtrate isremoved under reduced pressure and dried. The crude residue ischromatographed on a silica gel 60 column (230-400 mesh) using 25% ethylacetate in hexane as an elution solvent. The fractions containing thedesired product are combined and the solvent removed under reducedpressure to yield 20.0 g (47%) of N-phenyl N-(1-chloro 3-carboxyphenyl)amine 9.

N,N′-Bis(2-dinitrophenyl)-2,3-diaminobenzoic acid 10

10.0 g (0.034 mole) of N-phenyl N-(1-chloro 3-carboxyphenyl) amine, 9and 5.20 g (0.038 mole) of 2-nitro aniline 1 are dissolved in 200 mLanhydrous dimethylformamide (DMF) solvent. To the magnetically stirredsolution, copper powder 0.22 g (0.0035 mole) and copper iodide 0.65 g(0.0034 mole) and sodium carbonate 3.62 g (0.034 mole) are added andheated under reflux in an oil bath. A slow stream of nitrogen gas ismaintained throughout the course of the reaction. The reaction mixtureis heated for 24 hours. Solvent from the reaction mixture is removedunder high vacuum and dried. The crude residue is dissolved in water andextracted three times each time with 150 mL methylene chloride. Thecombined methylene chloride extracts is washed with brine and water. Theorganic layer is dried over anhydrous sodium sulfate and filtered.Solvent from the filtrate is removed under reduced pressure and dried.The crude residue is purified by silica gel column chromatography using25% ethyl acetate in hexane as an elution solvent. Fractions containingthe desired compound are pooled and the solvent removed under reducedpressure to yield 8.0 g (60%) of desired compound 10.

N,N′-Bis(2-diaminophenyl)-2,3-diaminobenzoic acid 11

2.0 g (0.00.5 mole) of N,N′-Bis(2-dinitrophenyl)-2,3-diaminobenzoic acid10 is taken into a hydrogenation pressure bottle. 200 mL of 2% glacialacetic acid in absolute ethanol is added. To the suspension, 0.4 g of10% palladium on activated carbon is added. The reaction mixture iscatalytically reduced under hydrogen atmosphere using a parrhydrogenation apparatus at 60 PSI for 6 hours. The solution is filteredand the solvent removed under reduced pressure and dried. The cruderesidue is used as an acetate salt without further purification for thesubsequent reactions. The yield of the product is 50-60%.

2,3,8,9-diphenylenyl 5,6,11,12-bis orthocarboxydiphenylenyl-1,4,7,10-tetraazadodecane 12

1.0 g (0.002 mole) of N,N′-Bis(2-diaminophenyl)-2,3-diaminobenzoic aciddiacetate 11 and 0.47 (0.002 mole) of 2,3-dichloro benzoic acid aredissolved in 100 mL of anhydrous dimethylformamide solvent. To amagnetically stirred solution, copper powder 0.160 (0.1002 mole) andcopper iodide 0.38 g (0.002 mole) and sodium carbonate 1.0 g (0.01 mole)are added and heated under reflux in an oil bath. A slow stream ofnitrogen is maintained throughout the course of the reaction. Thereaction mixture is heated at 115 to 120° C. for 36 hours. Solvent fromthe reaction mixture is removed under reduced pressure and dried Thecrude residue is purified by reverse phase HPLC using aqueousacetonitrile containing acetic acid as a mobile phase. The fractionscontaining the desired product are combined and the solvent removedunder reduced pressure to give 50% of the desired compound,2,3,8,9-diphenylenyl 5,6,11,12-bis orthocarboxy-diphenylenyl-1,4,7,10-tetraazadodecane 12.

2,3,8,9-diphenylenyl 5,6,11,12-bis orthocarboxydiphenylenyl-1,4,7,10-tetraazacyclododecaneN,N′,N″,N″′-tetraacetic acid 13

To a stirred suspension of 10.0 g (0.022 mole) 2,3,8,9-diphenylenyl5,6,11,12-bis ortho carboxydiphenylenyl-1,4,7,10-tetraazacyclododecane12 in 200 mL distilled water, 30.8 g (0.22 mole) of bromoacetic acid isadded and magnetically stirred. The pH of the solution is adjusted to10.0 with 2.0 N sodium hydroxide and the reaction mixture is heated inan oil bath at 45° C. for 20 hours. The pH of the reaction solution ismaintained between 9.75 and 10.0 with 5.0 N sodium hydroxide during theentire course of reaction. The progress of the reaction is monitored byHPLC using PRP-X100 anion exchange column and small amounts ofbromoacetic acid (i.e., 100 to 200 mg) are added to the reaction mixtureto drive the reaction to completion. The reaction mixture is dilutedwith sterile water to a 2 liter volume and the pH is adjusted to 6.8with 6.0 N hydrochloric acid. The conductivity for this solution is 4.89ms/cm. It is further diluted to 4 liters with sterile water and the pHis adjusted to 8.2 with 2.0 N sodium hydroxide. The measuredconductivity is 2.89 ms/cm. This solution is loaded on 5×60 cm columnwith 900 mL bed volume of AG® 1-X2 (acetate form) resin which isprewashed with 1 liter 1.5 M acetic acid, 1.5 liter water, 0.5 liter0.02 N ammonium acetate pH 7.18 and 4 liter water final eluent pH 4.28by FPLC at 40 mL/min. The column is eluted with water and solvent B(1.50 M acetic acid) of the gradient system is gradually increased.Fractions containing the product are pooled and solvent evaporated anddried under high vacuum to give 5.6 g (40%) of pure compound 13.

2,3,8,9-diphenylenyl 5,6,11,12-bis orthocarboxydiphenylenyl-1,4,7,10-tetraazacyclododecaneN,N′,N″,N″′-tetramethylene phosphonic acid 14

25.0 g (0.31 mole) of phosphorous acid and 20 mL of degassed water aretaken into a 3 neck round bottom flask equipped with a dropping funnel,a thermometer, and a magnetic stir bar. The flask is flushed withnitrogen gas and a slow stream of nitrogen is maintained in the reactionflask. Dissolution of the phosphorous acid is achieved upon stirring.15.0 mL of concentrated hydrochloric acid is added to the reactionmixture and the stirring continued. The dropping funnel is charged with20.0 g (0.044 mole) of 2,3,8,9-diphenylenyl 5,6,11,12-bis orthocarboxydiphenylenyl 1,4,7,10-tetraazacyclododecane, 12 dissolved in 25mL water. The cyclic tetramine solution from the dropping funnel isadded dropwise to the stirred acidic solution under nitrogen atmosphere.After completion of addition, the reaction mixture is heated underreflux using an oil bath for at least 1.0 hour. The dropping funnel ischarged with formaldehyde 27.2 g (0.938 mole) of a 37% aqueous solutionand is added to the reaction mixture dropwise over a 2 to 3 hour timeinterval. The reaction mixture is continued heating under refluxthroughout the entire formaldehyde solution addition period. Aftercompletion of all of the formaldehyde solution, the reaction mixture iscontinuously stirred under reflux for an additional 3 to 4 hours. Thereaction solution is then allowed to cool and the product,2,3,8,9-diphenylenyl-1,4,7,10-bisortho-carboxydiphenylenyl-1,4,7,10-tetraazacyclododecaneN,N′,N″,N″′-tetramethylene phosphonic acid 14 is isolated from thereaction mixture and purified by ion exchange resin chromatography in40-50% yield.

Example IV N,N′-Bis(2-diaminophenyl)-1,3-propane N,N′-diacetic Acid2,2′-tetraacetic acid dianhydride 15 Conjugated with Annexin V

N,N′-Bis(2-diaminophenyl)-1,3-propane N,N′-diacetic Acid 2,2′-tetraacetic acid dianhydride 15

10.0 g (0.018 mole) of N,N′-Bis(2-diaminophenyl)-1,3-propanediaminohexaacetic acid 4 is placed in a 500 mL round bottom flask. To the flaskis added 200 mL of acetic anhydride. The reaction mixture is stirredmagnetically and heated under reflux for 48 hours. Solvent from thereaction mixture is removed under high vacuum and dried. The cruderesidue is purified by sublimation to yield 6.0 g (64%) ofN,N′-Bis(2-diaminophenyl)-1,3-propane N,N′-diacetic acid2,2′-tetraacetic acid dianhydride 15.

r-Annexin V Conjugation of N,N′-Bis(2-diaminophenyl)-1,3-propaneN,N′-diacetic acid 2,2′-tetraacetic acid dianhydride 16

N,N′-Bis(2-diaminophenyl)-1,3-propane N,N′-diacetic acid2,2′-tetraacetic acid dianhydride 15 precursor is offered to r-Annexin Vin molar ratios of 300:1, 150:1, 75:1, 25:1, 10:1 and 5:1. Typically fora molar offering of 75:1 dianhydride to r-Annexin V ratio, 100 μl ofdimethyl sulfoxide or DMF solvent containing 7.74 mg of N₄ liganddianhydride is added dropwise with stirring to 2 mL of buffer with 25 mMHEPES ((N-[2-hydroxyethyl]piperazine-N′-[2-ethanesulfonic acid])), 150mM sodium chloride, pH 8.0 containing 7.2 mg of r-Annexin V. Thereaction mixture is stirred for 2 hours at 25° C.-37° C. followed bypurification by PD-10 size exclusion chromatography equilibrated in PBS.The final product of the conjugate is exhaustively dialyzed in PBS.

Example V Tc^(99m) radiolabeled N,N′-Bis(2-diaminophenyl)-1,3-propaneN,N′-diacetic acid 2,2′-tetraacetic acid dianhydride 15

Example VI Y90-Labeled N,N′-Bis(2-diaminophenyl)-1,3-propanediaminohexacetic acid 4 andN,N′-Bis(2-diaminophenyl)-1,3-propane-diamino hexamethylene phosphonicacid 5

^(99m)Tc-radiolabeling Procedure for N₄ ligand-r-Annexin V Conjugate 16

Method A:

Stannous gluconate kits are prepared containing 5.0 mg sodium gluconate100 micrograms stannous chloride, 1.0 mg (1 mg/ml) of N₄ligand-r-Annexin V conjugate 16, and 0.1 to 1.0 mg of lactose. The pH ismaintained between 5 and 7 using hydrochloric acid, acetic acid orsodium hydroxide. To the stannous gluconate kit is added 1.0 mL sodiumpertechnetate (99mTcO⁻ ₄) with a specific activity of 50 mCi/mL The vialis thoroughly mixed and incubated at 25° C.-37° C. for 15′-30′. Thepercent formation of radiolabeled conjugate, remaining TcO₄, andhydrolyzed reduced technetium is determined by ITLC in 12% TCA asdeveloping solvent.

Method B:

Stannous tartrate kits are prepared in an evacuator vial under nitrogento contain 0.5 mL of disodium tartrate (10 mg/mL) and 0.1 mL stannouschloride (1.0 mg/mL in ethanol). The pH of the solution is kept between5 and 7, preferably 6.0. To this stannous tartrate solution is added 1.0mL of sodium pertechnetate at a specific concentration of 50 mCi/mL. Thereaction mixture is allowed to stand at room temperature. In anevacuated vial, 200 μl of sodium phosphate (0.5 M, pH 8.0 or 10.0) and1.0 mL of N,N′-Bis(2-diaminophenyl)-1,3-propanediamino hexaacetic acid,4 (1.0 mg/mL) are added successively. Then Tc-99m-tartrate (50 mCi) isadded, and the vial is incubated at 25° C.-37° C. for 15 ′-30′. Thepercent formation of radiolabeled N₄ ligand, remaining TcO₄, andhydrolyzed reduced technetium is determined by ITLC in various solventsas developing solvent systems.

⁹⁰Y Radiolabeling of Compound 4 (18)

To carrier-free 0.6 mCi Y-90 Cl₃ (10 μl, 50 mM HCl, NEN Dupont), 0.18 mgof compound 4 in 450 μl of 2.0 M NH₄OAc, pH 5.0, is added and thereaction mixture is allowed to proceed for 30 minutes at 80° C. Thepercent of ⁹⁰Y radiolabeling monitored by gradient HPLC system equippedwith a radiometric detector is greater than 99%.

⁹⁰Y Radiolabeling of Compound 5 (19)

To carrier free 0.6 mCi Y-90 Cl₃ (10 μl, 50 mM HCl, NEN Dupont), 18 mgof compound 5 in 450 μl of 2.0 M ammonium acetate, pH 7.0, is added andthe reaction mixture is allowed to proceed for 30 minutes at 80° C. Thepercent of ⁹⁰Y radiolabeling as monitored by a gradient HPLC systemequipped with a radiometric detection is greater than 99%.

Example VII 4-N,N′-Bis(3-diaminothiophenyl)-1,3-propanediaminohexaacetic acid 23 and4-N,N′-Bis(3-diaminothiophenyl)-1,3-propanediamino hexamethylenephosphonic acid 24

4-N,N′-Bis(3-dintirothiophenyl)-1,3-propyl diamine 21

To a stirred solution of 25.0 g (0.174 mole 3-nitro 4-aminothiophene and10.2 g (0.034 mole) of 1,3-diiodopropane in 200 mL of dry dimethylsulfoxide, 18.3 g (0.172 mole) of sodium carbonate is added and heatedat 110° C.-115° C. for 12 hours. Solvent from the reaction mixture isremoved under high vacuum and dried The crude residue is purified bysilica gel column chromatography using 30% ethyl acetate in hexane as anelution solvent. Fractions containing the product are combined andsolvent removed under reduced pressure to yield 8.0 g (14%) of compound21.

4-N,N′-Bis(3-diaminothiophenyl)-1,3-propyldiamine 22

5.0 g (0.015 mole) of 4-N,N′-Bis(3-dinitrothiophenyl)-1,3-propyldiamine21 is taken into a hydrogenation bottle. 250 mL of 2% glacial aceticacid in absolute ethanol is added. To the suspension, 0.5 g of 10%palladium on activated carbon is added. The reaction mixture iscatalytically reduced under hydrogen atmosphere at 60 PSI for 4-6 hoursin a parr hydrogenation apparatus. The solution is filtered and thesolvent removed under reduced pressure and dried. The crude residue istaken into a saturated sodium bicarbonate solution and the free amine isextracted into methylene chloride three times each time with 150 mLvolume. The combined organic layer is dried over anhydrous sodiumsulfate and filtered. Solvent from the filtrate is removed under reducedpressure and dried to yield crude residue. The crude product is purifiedby silica gel column chromatography using 50% ethyl acetate in hexane asan elution solvent. Fractions containing the desired product arecombined, solvent removed under reduced pressure and dried to yield 3.50g (75%) of compound 22.

4-N,N′-Bis(3-diaminothiophenyl)-1,3-propanediamino hexaacetic acid 23

To a stirred suspension of 5.0 g (0.016 mole) of4-N,N′-Bis(3-diaminothiophenyl)-1,3-propanediamine 22 in 100 mL ofdistilled water, 22.6 g (0.163 mole) of bromoacetic acid is added andmagnetically stirred. The pH of the solution is adjusted to 10.0 with2.0 N sodium hydroxide and the reaction mixture is heated in an oil bathat 45° C. for 16 hours The pH is maintained between 9.75 and 10.0 with5.0 N sodium hydroxide during the entire course of reaction. Progress ofthe reaction is monitored by HPLC using PRP-X100 anion exchange columnand small amounts of bromoacetic acid is added to the reaction mixtureto drive the reaction to completion. The reaction mixture is dilutedwith sterile water to 2 liter volume and the pH is adjusted to 6.8 with6.0 N hydrochloric acid. The conductivity for this solution is 4.89Ms/cm. It is further diluted to 4 liters with sterile water and the pHis adjusted to 8.2 with 2.0 N sodium hydroxide. The measuredconductivity is 2.89 Ms/cm. This solution is loaded on 5×60 cm columnwith 900 mL bed volume of AG® 1-X2 (acetate form) resin which isprewashed with 1 liter 1.50 M acetic acid, 1.5 liter water, 0.5 liter0.02 M ammonium acetate pH 7.18 and 4 liter water final eluent pH 4.28by FPLC at 40 mL/min. The column is eluted with water and graduallyincreased the solvent B (1.50 M acetic acid) of the gradient system.Fractions containing the product are pooled, solvent evaporated anddried under high vacuum to give 7.50 g (81%) of compound 23.

4-N,N′-Bis (3-diaminothiophenyl) 1,3-propanediamino hexamethylenephosphonic acid 24

25.0 g (0.31 mole) of phosphorous acid and 25 mL of degassed water aretaken into a 3 neck round bottom flask equipped with a dropping funnel,a thermometer and a magnetic stirring bar. The flask is flushed withnitrogen gas and a slow stream of nitrogen is maintained in the flask.dissolution of the phosphorous acid is achieved upon stirring. 30 mL ofconcentrated hydrochloric acid is added to the reaction mixture andstirring continued. The dropping funnel is charged with 20.0 g (0.065mole) of 4-N,N′-Bis(3-diaminothiopheynl)-1,3-propanediamine dissolved in25 mL of water. The amine solution from the dropping funnel is addeddropwise to the magnetically stirred acidic solution under nitrogenatmosphere. After completion of addition the reaction mixture is heatedunder reflux using an oil bath for at least 1.0 hour. Then the droppingfunnel is charged with formaldehyde 22.0 g (0.73 mole) of a 37% aqueoussolution and is added to the reaction mixture dropwise over a 2-3 hourtime interval. The reaction mixture is continued heating under refluxthroughout the entire formaldehyde solution addition period. Aftercompletion of all of the formaldehyde solution, the reaction mixture iscontinued stirring under reflux for an additional 4-6 hours The reactionmixture is then allowed to cool and the product4-N,N′-Bis(3-diaminothiophenyl)-1,3-propanediamino hexamethylenephosphonic acid 24 is isolated from the reaction mixture and purified byion exchange resin chromatography.

Example VIII 2,3,9,10-[2,3-C,9,10-C)-dithiophenyl]-1,4,8,11-tetraazacyclo tetradecaneN,N′,N″,N″′-tetraacetic acid 26 and2,3,9,10-[2,3-C,9,10-C)-dithiophenyl]-1,4,8,11-tetraazacyclo tetradecaneN,N′,N″,N″′-tetramethylene phosphonic acid 27

2,3,9,10-[(2,3-C; 9,10-C′)-dithiophenyl]-1,4,8,11-tetraazacyclotetradecane 25

A stirred solution of 10.0 g (0.037 mole) of4-N,N′-Bis(3-diaminothiophenyl)-1,3-propanediamine 22, 2.0 g (0.007mole) of 1,3-diiodopropane and 5.70 g (0.068 mole) of sodium bicarbonatein 100 mL dry dimethyl sulfoxide is heated at 115° C. for 4 hours undernitrogen atmosphere. The dimethyl sulfoxide solvent is removed underhigh vacuum and dried. The crude product is extracted three times eachtime with 100 mL methylene chloride by partitioning with water. Thecombined methylene chloride layer is washed with brine and water. Theorganic layer is dried over anhydrous sodium sulfate and filtered.Solvent from the filtrate is removed under reduced pressure to yieldcrude residue. The crude residue is purified by flash chromatography ona silica gel column using 25% ethyl acetate in hexane as an elutionsolvent. The fractions containing the product are combined and thesolvent removed under reduced pressure and dried to yield 4.0 g (35%) ofcompound 25.

2,3,9,10-[(2,3-C, 9,10-C)-dithiophenyl]-1,4,8,11-tetraazacyclotetradecane N,N′,N″,N″′-tetraacetic acid 26

To a stirred suspension of 10.0 g (0.033 mole) of compound 25 in 200 mLof distilled water, 40.0 g (0.288 mole) of bromoacetic acid is added.The reaction mixture is stirred magnetically at room temperature. The pHof the solution is adjusted to 10.0 with 2.0 N sodium hydroxide and thereaction mixture is heated in an oil bath at 45° C. for 20 hours. The pHis maintained between 9.75 and 10.0 with 5.0 N sodium hydroxide duringthe entire course of reaction. Progress of the reaction is monitored byHPLC using PRP-X100 anion exchange column and small amounts ofbromoacetic acid (i.e., 100-200 mg) are added to the reaction mixture todrive the reaction to completion. The reaction mixture is diluted withsterile water to 2 liter volume and the pH is adjusted to 6.8 with 6.0 Nhydrochloric acid The conductivity for this solution is 4.89 Ms/cm. Itis further diluted to 4 liters with sterile water and the pH is adjustedto 8.2 with 2.0 N sodium hydroxide. The measured conductivity is 2.89Ms/cm. This solution is loaded on 5×60 cm column with 900 mL bed volumeof AG® 1-X2 (acetate form) resin which is prewashed with 1 liter 1.5 Macetic acid, 1.5 liter water, 0.5 liter 0.02 M ammonium acetate pH 7.18and 4 liter water final eluent pH 4.28 by FPLC at 40 mL/min. The columnis eluted with water and gradually increased the solvent B (1.50 Macetic acid) of the gradient system. Fractions containing the productare pooled and solvent evaporated and dried under high vacuum to give8.0 g (46%) of compound 26.

2,3,9,10-[(2,3-C, 9,10-C)-dithiophenyl]-1,4,8,11-tetraazacyclotetradecane N,N′,N″,N″′-tetramethylene phosphonic acid 27

5.0 g (0.061 mole) of phosphorous acid and 10 mL of degassed water aretaken into a 3 neck round bottom flask equipped with a dropping funnel,a thermometer and a stir bar. The flask is flushed with nitrogen gas anda slow stream of nitrogen is maintained in the flask. Dissolution of thephosphorous acid is achieved upon stirring. 10.0 mL of concentratedhydrochloric acid is added to the reaction mixture and the stirringcontinued. The dropping funnel is charged with 4.0 g (0.013 mole) of2,3,9,10-[(2,3-C, 9,10-C)-dithiophenyl]-1,4,8,11-tetraazacyclotetradecane 25 dissolved in 15 mL water. The cyclic amine solution fromthe dropping funnel is added dropwise to the stirred acidic solutionunder nitrogen atmosphere. After completion of addition, the reactionmixture is heated under reflux using an oil bath for at least 1.0 hour.Then the dropping funnel is charged with formaldehyde 5.0 g (0.172 mole)of a 37% aqueous solution and is added to the reaction mixture dropwiseover a 2 to 3 hour time period. The reaction mixture is continuedheating under reflux throughout the entire formaldehyde solutionaddition. After completion of all of the formaldehyde solution, thereaction mixture is continuously stirred under reflux for an additional3 to 4 hours. The reaction mixture is then allowed to cool and theproduct 2,3,9,10-[(2,3-C;9,10-C′)-dithiophenyl]-1,4,8,11-tetraazacyclotetradecaneN,N′,N″,N″′-tetramethylene-phosphonic acid 27 is isolated from thereaction mixture and purified by ion exchange chromatography in 25%yield.

Example IX 4-N,N′-Bis(3-diaminothiophenyl) 1,3-propanediaminohexamethylene phosphonic acid 24 and 2,3,9,10-[(2,3-C,9,10-C)-dithiophenyl]-1,4,8,11-tetraazacyclo tetradecaneN,N′,N″,N″′-tetramethylene phosphonic acid 27 is Y⁹⁰ Labeled

⁹⁰Y-Radiolabeling of Compound 24 (28)

To carrier free 0.6 mCi Y-90 Cl₃ (10 μl, 50 mM HCl, NEN Dupont), 0.18 mgof compound 24 in 450 μl of 2.0 M ammonium acetate, pH 5.0, is added andthe reaction mixture is allowed to proceed for 30 minutes at 80° C. Thepercent of ⁹⁰Y-radiolabeling monitored by a gradient HPLC systemequipped with a radiometric detector is greater than 99%.

⁹⁰Y-Radiolabeling of Compound 27 (29)

To carrier free 0.6 mCi Y-90 Cl₃ (10 μl, 50 mM HCl, NEN Dupont), 180 mgof compound 27 in 450 μl of 2.0 M ammonium acetate, pH 7.0, is added andthe reaction mixture is allowed to proceed for 30 minutes at 80° C. Thepercent of ⁹⁰Y-radiolabeling monitored by gradient HPLC system equippedwith a radiometric detection is greater than 99%.

Example X Biocytin Conjugated on Tc^(99m) RadiolabeledN,N′-Bis(2-diaminophenyl)-1,3-propane N,N′-diacetic Acid2,2′-tetraacetic acid dianhydride 15

Biocytin Conjugation of N,N′-Bis(2-diaminophenyl)-1,3-propaneN,N′-diacetic acid 2,2′-tetraacetic acid dianhydride 15 (20)

Typically to a stirred beaker of 25.0 mL of 0.20 M borate, pH 8.0, isadded in sequential order 1.25 mL of dimethylformamide containing 129 mg(0.25 m moles) of N,N′-Bis(2-diaminophenyl)-1,3-propane N,N′-diaceticacid 2,2′-tetraacetic acid dianhydride chelate followed by 1.25 mL ofDMF containing 9.3 mg (0.025 m moles) of biocytin free base. Afterincubation at 25° C. for 2 hours with stirring, the desired product isseparated from the reactants and side products by preparative reversephase C-18 chromatography, such as the DYNAMAX®-60A (supplied by RaininInstrument Co.).

Alternatively in a stirred beaker of 25 mL of dimethylformamide is added1.25 mL DMF containing 124 mg (0.25 m moles) of N₄-dianhydride chelate15, 1.25 mL of DMF containing 9.3 mg (0.025 m moles) of biocytin freebase and 1.25 mL of DMF containing 0.025 m moles of diisopropylethylamine. The reaction mixture is stirred at room temperatureovernight. The desired product is purified by reverse phase C-18chromatography.

The in vitro binding efficacy of the biocytin derivatized N₄ chelate toavidin or streptavidin is assessed using the standard HABA([2(4′hydroxy-azobenzene)benzoic acid]dye) UV/VIS spectrophotometricassay of Green et al. (Biochem. J., 94:23c-24c, 1965). The radiolabelingwith radioactive metals ⁹⁰Y and ¹¹¹In is performed in 2.0 M acetatebuffer, pH 5.0 as described earlier in labeling the N₄ tetramethylenephosphonate ligands.

Example XIN,N′-Bis(2,disulfidyl-4-ethoxycarbonylphenyl)-1,3-propyldiamine

4,4-Diethoxycarbonylpropyl-1,3-dianiline 31

A stirred solution of 2.065 g (1.25 mole) ethyl-4-amino benzoate 3,14.35 mL (0.125 mole) 1,3-diidopropane and 10.5 g (0.125 mole) sodiumbicarbonate in 500 mL dry dimethyl sulfoxide was heated at 110° C. for 3hours under nitrogen. Upon cooling, the mixture was poured into 2 L ofice water with stirring and the resulting precipitate collected byfiltration. The precipitate was then washed with glacial acetic acid(14×75 mL) until all of the starting ethyl-4-aminobenzoate had beenremoved. After drying in vacuo, the product, 31, thus obtained was usedin the next step without further purification.

1,3-di(2-imino-6-ethoxycarbonylbenzthiazolyl-3-)propane 32

Ammonium thiocyanate (16.5 g, 0.217 mole) was added to a magneticallystirred suspension of 4,4-diethoxycarbonylpropyl-1,3-dianiline (10.0 g,0.027 mole) (prepared as described above) in 1500 mL glacial aceticacid. A solution of bromide (34.6 g, 0.216 mole) in 100 mL glacialacetic acid was then added dropwise to the suspension with stirring atroom temperature. After stirring the reaction mixture overnight at roomtemperature, the dihydrobromide salt of the crude product was collectedby filtration and dried. The product, 32, was isolated by dissolving thecrude product in hot water, adjusting to basic pH with the addition ofsaturated sodium bicarbonate solution, collecting the precipitate byfiltration, and drying in vacuo.

N,N′-Bis(2-disulfidyl-4-carbonylphenyl)-1,3-propyldiamine 33

Solid potassium hydroxide (20.0 g, 0.357 mole) was added to a suspensionof the (1.0 g, 0.002 mole) 32 in 40 mL distilled water, and theresulting mixture was heated at 120° C. for 12 hours. Completedissolution occurred after 1 hour. The reaction mixture was then cooledin an ice bath and the pH was adjusted to 5.0 with 5.0 N acetic acid.The aqueous solution was then extracted with three 100 mL portions ofethyl acetate The combined ethyl acetate extracts were dried overanhydrous sodium sulfate and the drying agent was filtered. Removal ofsolvent yielded the product 33.

N,N′-Bis(2-disulfidyl-4-ethoxycarbonylohenyl)-1,3-propyldiamine 34

A magnetically stirred suspension of 33 (0.5 g, 0.0013 mole) in 200 mLabsolute ethyl alcohol was saturated with dry hydrogen chloride gas. Thereaction mixture was then heated under reflux for 3 days. Upon cooling,the solvent was removed under reduced pressure, to yield the product,34, as its dihydrochloride salt. A solution of the salt in 100 mLdistilled water was adjusted to pH 8.5 to 9.0 with 0.2 M sodiumbicarbonate solution and the aqueous solution was extracted with three100 mL portion methylene chloride The combined methylene chlorideextracts were dried over anhydrous sodium sulfate and the drying agentfiltered Removal of the solvent under reduced pressure gave the crudeproduct 34 which was isolated and purified by flash chromatography usingsilica gel and eluting with methylene chloride and ethyl acetate.

N,N′-Bis(2-disulfidyl-4-carboxyphenyl)-1,3-propyldiamine N,N′-diaceticacid 35

To a stirred suspension of 10.0 g (0.023 mole) of 34 in 200 mL distilledwater, 40.0 g (0.288 mole) of bromoacetic acid is added. The reactionmixture is stirred magnetically at room temperature The pH of thesolution is adjusted to 10.0 with 2.0 N sodium hydroxide and thereaction mixture is heated in an oil bath at 45° C. for 16 hours. The pHis maintained between 9.75 and 10.0 with 5.0 N sodium hydroxide duringthe entire course of reaction. The progress of the reaction is monitoredby HPLC using PRP-X100 anion exchange column and small amounts ofbromoacetic acid is added to the reaction mixture to drive the reactionto completion. The reaction mxiture is diluted with sterile water to 2liter volume and the pH is adjusted to 6.8 with 6.0 N hydrochloric acid.The conductivity for this solution is 4.89 ms/cm. It is further dilutedto 4 liters with sterile water and the pH is adjusted to 8.2 with 2.0 Nsodium hydroxide. The measured conductivity is 2.89 ms/cm. This solutionis loaded on 5×60 column with 900 mL bed volume of AG® 1-X2 (acetateform) resin which is prewashed with 1 liter 1.5 M acetic acid, 1.5 literwater, 0.5 liter 0.02 N ammonium acetate pH 7.18 and 4 liter water finaleluent pH 4.28 by FPLC at 40 mL/min. The column is eluted with water andsolvent B (1.50 M acetic acid) of the gradient system is graduallyincreased. Fractions containing the product are pooled and solventevaporated and dried under high vacuum to give 7.10 g (40%) of compound35.

Tc-99m Radiolabeling ofN,N′-Bis(2-disulfidyl-4-carboxyphenyl)-1,3-propyldiamine N,N′-diaceticacid 36

A solution of 0.6 mL of 170 μg/mLN,Nμ-bis(2-disulfidyl-4-ethoxylcarbonylphenyl)-1,3-propyldiamineN,N′-diacetic acid in either acetonitrile or isopropanol is added to 1.1mL of Tc-99m gluconate (prepared from 0.12 mg stannous chloridedihydrate, 5.0 mg sodium gluconate at pH 6.1-6.3, and 100 mCi/mL ofTc-99m pertechnetate). The resulting mixture is incubated either at roomtemperature for 15-30 minutes or heated at 75° C. for 2-5 minutesfollowed by cooling with an ice bath. The crude reaction mixture is thendiluted with 3 mL water and purified by reverse phase chromatography.The crude product is loaded onto a pre-conditioned C-18 samplepreparation cartridge (SPICE™ cartridge supplied by Analtech) and elutedwith 5 mL water followed by 10 mL 5% ethanol-saline, and 10 mL 10%ethanol saline, respectively. The Tc-99m chelate product is eluted with10 mL 50% ethanol-saline to give 75% radiochemical yield of the desiredproduct. The radiochemical purity of the eluent is analyzed by reversephase C-18 isocratic liquid chromatography using 50% ethanol-saline asthe mobile phase at a flow rate of 0.8 mL per minute.

All publications and patent applications mentioned in this specificationare herein incorporated by reference to the same extent, as if eachindividual publication or patent application is specifically andindividually incorporated by reference

From the foregoing, it will be appreciated that, although specificembodiments of the invention have been described herein for the purposeof illustration, various modifications may be made without deviatingfrom the spirit and scope of the invention.

1. A complex of the formula:

wherein: M is a radionuclide metal or an oxide or nitride thereof: n=0or 1; R₁ and R₂ are independently selected from hydrogen, ═O, with theproviso that both are not ═O, —(CH₂)_(m)-Z where m is 0-10 and Zrepresents a conjugation group or targeting moiety, and —(CH₂)_(m)—Wwhere m is 0-10 and W represents a hydrolyzable group, or R₁ and R₂ aretaken together to form a cyclic anhydride or a benzene ring; R₃ ishydrogen, lower alkyl, alkoxy, halogen, hydroxyl, nitro, —(CH₂)_(m)-Z or—(CH₂)_(m)—W; R₄ and R₅ are attached at one or more of the ringpositions and are independently selected from hydrogen, lower alkyl,alkoxy, halogen, hydroxyl, nitro, —(CH₂)_(m)-Z and —(CH₂)_(m)—W; R₆ andR₇ are independently selected from hydrogen with the proviso that bothare not hydrogen, lower alkyl, alkoxy, halogen, hydroxyl, nitro,—(CH₂)_(m)-Z, —(CH₂)_(m)—W— and

where Q represents a multivalent acid functionality group able tocoordinate with metal ions, and p=0 to 1; R₁₂ and R₁₃ are independentlyselected from hydrogen, hydroxyl, carboxyl, phosphoric, and hydrocarbonradicals having from 1-10 carbon atoms, and physiologically acceptablesalts of the acid radicals; X, X′, Y and Y′ are carbon, to form memberaromatic rings; A and A′ are oxygen, where an oxygen may bear ahydrogen; and the complex has at least one Z, W or Q.
 2. A complexaccording to claim 1, wherein: R₁ and R₂ are independently selected fromhydrogen, ═O, with the proviso that both are not ═O, and —(CH₂)_(m)-Zwhere m is 0-10 and Z represents a conjugation group or targetingmoiety, or R₁, and R₂ are taken together to form a cyclic anhydride or abenzene ring; R₃ is hydrogen, lower alkyl, alkoxy, halogen, hydroxyl,nitro or —(CH₂)_(m)-Z; R₄ and R₅ are attached at one or more of the ringpositions and are independently selected from hydrogen, lower alkyl,alkoxy, halogen, hydroxyl, nitro and —(CH₂)_(m)-Z; R₆ and R₇ areindependently selected from hydrogen with the provision that both arenot hydrogen, lower alkyl, alkoxy, halogen, hydroxyl, nitro and—(CH₂)_(m)-Z or

X, X′, Y and Y′ are defined as in claim 1; A and A′ are defined as inclaim 1; and said complex has at least one Z or Q.
 3. A complexaccording to claim 2, wherein n=1; R₁, R₂, R₃ are hydrogen; R₄ and R₅are independently selected from hydrogen and —(CH₂)_(m)-Z; R₆ and R₇ are

p=0, R₁₂ and R₁₃ are hydrogen, Q is a multivalent acid functionalitycapable of coordinating with metal ions; A and A′ are defined as inclaim
 1. 4. A complex according to claim 2, wherein n=0; R₁ and R₂ aretaken together to form a benzene ring; R₄ and R₅ are independentlyselected from hydrogen and —(CH₂)_(m)-Z; R⁶ and R⁷ are

wherein Q is independently selected from a phosphonic acid and acarboxylic acid, p=0, and R₁₂ and R₁₃ are hydrogen.
 5. A complexaccording to claim 2, wherein n=1; R₁, R₂ and R₃ are hydrogen; R₄, andR₅ are independently selected from hydrogen and —(CH₂)_(m)-Z; R₆ and R₇are

wherein Q is independently selected from a phosphonic acid and acarboxylic acid, p=0, and R₁₂ and R₁₃ are hydrogen; with the provisothat said compound has at least one Z.
 6. A complex according to claim5, wherein Z is a targeting moiety selected from antibody fragments,biotin or annexin.
 7. A complex according to claim 1, wherein: R₁ and R₂are independently selected from hydrogen, ═O, with the proviso that bothare not ═O, and —(CH₂)_(m)—W where m is 0-10 and W represents ahydrolyzable group, or R₁ and R₂ are taken together to form a cyclicanhydride or a benzene ring; R₃ is hydrogen, lower alkyl, alkoxy,halogen, hydroxyl, nitro or —(CH₂)_(m)—W; R₄ and R₅ are attached at oneor more of the ring positions and are independently selected fromhydrogen, lower alkyl, alkoxy, halogen, hydroxyl, nitro and—(CH₂)_(m)—W; R₆ and R₇ are independently selected from hydrogen, loweralkyl, alkoxy, halogen, hydroxyl, nitro, —(CH₂)_(m)—W and

and said compound has at least one W.
 8. A complex according to claim 7,wherein n=1; R₁, R₂ and R₃ are hydrogen; R₄ and R₅ are independentlyselected from hydrogen and —(CH₂)_(m)—W; R₆ and R₇ are

Q are independently selected from a phosphonic acid and a carboxylicacid, p=0, and R₁₂ and R₁₃ are hydrogen.
 9. A complex of claim 8 whereinW is elected from the group consisting of ester, carbamate and nitrile.10. A complex according to any one of claims 1-9, wherein theradionuclide is a radionuclide of technetium, copper, rhenium, lead,bismuth, ruthenium, rhodium, yttrium, samarium, holmium, indium, gold orpalladium.
 11. A complex according to claim 10, wherein the radionuclideis a radionuclide of technetium, rhenium, indium or yttrium.
 12. Acomplex according to claim 10, wherein the radionuclide is aradionuclide of samarium.
 13. A complex according to claim 10, whereinthe radionuclide is a radionuclide of holmium.